UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 10-Q

1	Mark	One	۱
٠,	MIAIN	One	,

\boxtimes	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
	For the quarterly period ended October 31, 2021.
	or
	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
	For the transition period from to
	Commission File Number 001-06991
	Walmart
	WALMART INC.

Delaware

(State or other jurisdiction of incorporation or organization)
702 S.W. 8th Street

Bentonville AR (Address of principal executive offices) 71-0415188 (I.R.S. Employer Identification No.)

> 72716 (Zip Code)

Registrant's telephone number, including area code: (479) 273-4000 Former name, former address and former fiscal year, if changed since last report: N/A

(Exact name of registrant as specified in its charter)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.10 per share	WMT	New York Stock Exchange
1.900% Notes Due 2022	WMT22	New York Stock Exchange
2.550% Notes Due 2026	WMT26	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all repshorter periods that the registrant was required to file such reports	*	ties Exchange Act of 1934 during the preceding 12 months (or such a past 90 days. Yes \boxtimes No \square
Indicate by check mark whether the registrant has submitted elec chapter) during the preceding 12 months (or for such shorter peri		
Indicate by check mark whether the registrant is a large accelerate of "large accelerated filer," "accelerated filer," "smaller reporting		eporting company, or an emerging growth company. See definitions of the Exchange Act.
Large Accelerated Filer	Accelerated Filer	
Non-Accelerated Filer	Smaller Reporting Company	y \square
	Emerging Growth Company	
If an emerging growth company, indicate by check mark if the restandards provided pursuant to Section 13(a) of the Exchange Ac	*	or complying with any new or revised financial accounting
Indicate by a check mark whether the registrant is a shell compar	y (as defined in Rule 12b-2 of the Exchange Act). Yes \Box	No ⊠
The registrant had 2,773,878,458 shares of common stock outstand	nding as of November 29, 2021.	

Walmart Inc. Form 10-Q For the Quarterly Period Ended October 31, 2021

Table of Contents

		Page
Part I. Fina	ncial Information	
	Item 1. Financial Statements	
	Condensed Consolidated Statements of Income	<u>3</u>
	Condensed Consolidated Statements of Comprehensive Income	<u>4</u>
	Condensed Consolidated Balance Sheets	<u>5</u>
	Condensed Consolidated Statements of Shareholders' Equity	<u>6</u>
	Condensed Consolidated Statements of Cash Flows	<u>8</u>
	Notes to Condensed Consolidated Financial Statements	<u>9</u>
	Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	17 28 28
	Item 3. Quantitative and Qualitative Disclosures About Market Risk	<u>28</u>
	Item 4. Controls and Procedures	<u>28</u>
Part II. Oth	ner Information	
	Item 1. Legal Proceedings	<u>29</u>
	Item 1A, Risk Factors	<u>31</u>
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	31 31
	Item 5. Other Information	<u>31</u>
	Item 6. Exhibits	<u>35</u>
<u>Signatures</u>		<u>36</u>
	2	

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Walmart Inc. Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended Octobe 31,		d October	Nir	ne Months Ei	nded October 31,		
(Amounts in millions, except per share data)		2021		2020		2021		2020
Revenues:				_		_		
Net sales	\$	139,207	\$	133,752	\$	416,237	\$	404,248
Membership and other income		1,318		956		3,646		2,824
Total revenues		140,525		134,708		419,883		407,072
Costs and expenses:								
Cost of sales		105,023		100,339		313,478		305,054
Operating, selling, general and administrative expenses		29,710		28,591		86,350		84,957
Operating income	' <u></u>	5,792		5,778		20,055		17,061
Interest:								
Debt		408		455		1,326		1,542
Finance lease		78		86		241		249
Interest income		(44)		(25)		(111)		(91)
Interest, net		442		516		1,456		1,700
Loss on extinguishment of debt		2,410		_		2,410		_
Other (gains) and losses		(1,207)		(1,853)		2,275		(5,796)
Income before income taxes	' <u></u>	4,147		7,115		13,914		21,157
Provision for income taxes		1,015		1,914		3,607		5,443
Consolidated net income	' <u></u>	3,132		5,201		10,307		15,714
Consolidated net income attributable to noncontrolling interest		(27)		(66)		(196)		(113)
Consolidated net income attributable to Walmart	\$	3,105	\$	5,135	\$	10,111	\$	15,601
Net income per common share:								
Basic net income per common share attributable to Walmart	\$	1.11	\$	1.81	\$	3.61	\$	5.51
Diluted net income per common share attributable to Walmart		1.11		1.80		3.59		5.48
Weighted-average common shares outstanding:								
Basic		2,785		2,833		2,799		2,832
Diluted		2,797		2,849		2,813		2,849
Dividends declared per common share	\$	_	\$	_	\$	2.20	\$	2.16

Walmart Inc. Condensed Consolidated Statements of Comprehensive Income (Unaudited)

	Three Months Ended October 31,			Nine Months Ende			ctober 31,	
(Amounts in millions)	2021		2020			2021		2020
Consolidated net income	\$ 3	3,132	\$ 5	201	\$	10,307	\$	15,714
Consolidated net income attributable to noncontrolling interest		(27)		(66)		(196)		(113)
Consolidated net income attributable to Walmart	3	3,105	5	135		10,111		15,601
Other comprehensive income (loss), net of income taxes								
Currency translation and other		(523)	1	262		2,637		(2,408)
Net investment hedges		_		(1)		(1,202)		(35)
Cash flow hedges		(183)		_		(318)		34
Minimum pension liability		1		16		1,972		47
Other comprehensive income (loss), net of income taxes		(705)	1	277		3,089		(2,362)
Other comprehensive (income) loss attributable to noncontrolling interest		193	(109)		189		551
Other comprehensive income (loss) attributable to Walmart		(512)	1	168		3,278		(1,811)
Comprehensive income, net of income taxes	2	2,427	6	478		13,396		13,352
Comprehensive (income) loss attributable to noncontrolling interest		166	(175)		(7)		438
Comprehensive income attributable to Walmart	\$ 2	2,593	\$ 6	303	\$	13,389	\$	13,790

Walmart Inc. Condensed Consolidated Balance Sheets (Unaudited)

ASSETS Current assets: \$ 16,111 s \$ 7,484 s \$ 16,111 s \$ 7,484 s \$ 16,111 s \$ 7,484 s \$ 16,111 s \$ 16,111 s \$ 16,111 s \$ 17,484 s \$ 17,4	January 31, 2021	October 31, 2020		
Cash and cash equivalents \$ 16,111 s Receivables, net 7,349 Inventiones 57,484 Prepaid expenses and other 82,994 Property and equipment, net 92,22 Operating lease right-of-use assets 13,863 Finance lease right-of-use assets, net 28,933 Office lease right-of-use assets, net 22,033 Office lease right-of-use assets, net 22,033 Total assets 22,033 Total assets \$ 24,521 Codewill 28,233 Total assets \$ 24,521 Short-term borrowings \$ 447 Account spayable 51,156 Dividents payable 1,575 Accound inabilities 24,474 Accound inabilities 446 Long-term debt due within one year 1,486 Operating lease obligations due within one year 1,486 Total current liabilities 36,425 Long-term debt due within one year 1,486 Total current liabilities 31,935 Long-term debt due within one year 1,935 </th <th></th> <th></th>				
Receivables, net 7,349 Inventories 57,484 Prepate expenses and other 2,205 Total current assets 82,964 Property and equipment, net 92,242 Operating lease right-of-use assets 4,265 Goodwil 22,933 Other long-stem assets, net 22,933 Other long-stem assets 22,633 Total assets 22,433 Total assets 24,451 Short-term bertified to the stem asset in				
Inventories 57,484 Propad expense and other 2,020 Total current assets 82,964 Property and equipment, net 92,242 Operating lease right-of-use assets, net 4,266 Goodwill 28,93 Other long-term assets 2,263 Total assets 8,244,81 Short-term based to the stabilities Short-term borrowings 8,47 Accounts payable 57,156 Dividends payable 57,156 Accounted inibilities 24,474 Accorded income taxes 4,46 Long-term debt due within one year 1,578 Operating lease obligations due within one year 58 Finance lease obligations due within one year 58 Total current flabilities 36,425 Long-term operating lease obligations 13,095 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term depting lease obligations 2,77 Long-term operating lease obligations 13,095 Long-term finance lease obligat	\$ 17,741	\$ 14,325		
Prepaid expenses and other 2,020 Total current assets 82,964 Property and equipment, net 92,242 Operating lease right-of-use assets 13,863 Finance lease right-of-use assets, net 4,226 Goodwill 28,923 Other long-term assets 22,633 Total assets \$ 244,851 Child Interest the provision of the provis	6,516	5,770		
Total current assets	44,949	51,842		
Property and equipment, net 92,242 Operating lease right-of-use assets 13,863 Finance lease right-of-use assets, net 4,226 Goodwill 28,923 Total assets 24,4851 Total assets 24,474 Accounts payable 1,288 Accounts payable 1,288 Account in abilities 24,474 Accounted income taxes 44,674 Accounted income taxes 44,674 Accounted income taxes 44,674 Total current liabilities 36,425 Total current liabil	20,861	1,665		
Operating lease right-of-use assets, net 4,226 Goodwill 28,93 Other long-term assets 22,633 Total asset \$ 24,831 LABILITIES AND EQUITY Current liabilities: Short-term borrowings \$ 447 Accounts payable 57,155 Dividends payable 1,528 Accrued income taxes 446 Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 3,625 Total current liabilities 37,620 Long-term debt due within one year 1,486 Finance lease obligations due within one year 1,575 Total current liabilities 3,625 Long-term operating lease obligations 4,061 Long-term operating lease obligations 4,061 Defered income taxes and other 12,893 Commitments and contingencies Equity: Common stock 2,77 Capital in excess of par value 8,564 Accum	90,067	73,602		
Finance lease right-of-use assets, net 4,26 Goodwill 28,23 Other long-term assets 22,63 Total assets \$ 244,851 \$ LIABILITIES AND EQUITY Current liabilities Short-term borrowings \$ 447 \$ Accounts payable 57,155 \$ Dividends payable 1,528 \$ Accrued liabilities 24,474 \$ Accrued income taxes 446 \$ Long-term debt due within one year 1,575 \$ Operating lease obligations due within one year 5,808 \$ Total current liabilities 87,620 \$ Long-term debt 36,425 \$ Long-term operating lease obligations due within one year 13,095 \$ Long-term innance lease obligations 13,095 \$ Long-term operating lease obligations 13,095 \$ Commitments and contingencies \$ \$ Equity \$ 4,811 \$ Common stock <	92,201	102,232		
Godwill 28,923 Other long-term assets 22,633 Total assets \$ 244,851 LIABILITIES AND EQUITY Current liabilities Short-term borrowings \$ 447 A counts payable 57,156 Dividends payable 1,232 Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,486 Finance lease obligations due within one year 1,486 Finance lease obligations due within one year 87,620 Long-term debt 87,620 Long-term debt 1,486 Finance lease obligations due within one year 1,486 Finance lease obligations 36,425 Long-term debt 1,305 Long-term dept due within one year 1,305 Long-term dept due within one year 1,305 Long-term dept due contingencies 36,425 Commitments and contingencies 2,77 Cypital in excess of par value 4,811 Retained earnings 4,811 <	13,642	17,128		
Other long-term assets 22,633 Total assets \$ 244,851 \$ LIABILITIES AND EQUITY Current liabilities Short-term borrowings \$ 447 \$ Accounts payable 57,156 5 Dividends payable 1,228 4 Accrued liabilities 24,474 4 Accrued insome taxes 446 4 Long-term debt due within one year 1,575 5 Operating lease obligations due within one year 1,866 1 Finance lease obligations due within one year 87,620 87,620 Long-term debt 36,425 6 1 Long-term debt 36,425 6 1 4 6 1 6 4 6 1 6 2 7 6 1 8 6 2 7 7 1 6 4 0 1 9 1 4 0 1 0 2 7 2 1 3 2	4,005	4,929		
Total assets \$ 244,811 \$ LIABILITIES AND EQUITY Current liabilities Short-tem borrowings \$ 447 \$ Accounts payable \$ 1,528 \$ Dividends payable 24,474 \$ Accrued liabilities 24,474 \$ Accrued income taxes 446 \$ Long-term debt due within one year 1,486 \$ Operating lease obligations due within one year 8,620 \$ Total current liabilities 36,425 \$ Total current liabilities 36,425 \$ Long-term debt 36,425 \$ Long-term debt geas obligations due within one year 36,425 \$ Long-term debt 36,425 \$ Long-term debt geas obligations 36,425 \$ Long-term debt geas obligations 31,095 \$ Competence descriptions 32,725 \$ Equity 277 \$ \$ \$ \$ \$ \$ \$ \$ <td>28,983</td> <td>30,236</td>	28,983	30,236		
Current liabilities	23,598	22,736		
Current liabilities: \$ 447 \$ \$ \$ \$ \$ \$ 447 \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ 252,496	\$ 250,863		
Short-term borrowings \$ 447 \$ Accounts payable 57,156 Dividends payable 1,528 Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 508 Finance lease obligations due within one year 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757				
Accounts payable 57,156 Dividends payable 1,528 Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 1,86 Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term operating lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757				
Accounts payable 57,156 Dividends payable 1,528 Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term operating lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	\$ 224	\$ 240		
Dividends payable 1,528 Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 1,486 Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	49,141	54,152		
Accrued liabilities 24,474 Accrued income taxes 446 Long-term debt due within one year 1,486 Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term operating lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	_	1,529		
Accrued income taxes 446 Long-term debt due within one year 1,575 Operating lease obligations due within one year 508 Finance lease obligations due within one year 87,620 Long-term debt 36,425 Long-term debt 13,095 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	37,966	24,995		
Operating lease obligations due within one year 1,486 Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	242	548		
Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	3,115	4,358		
Finance lease obligations due within one year 508 Total current liabilities 87,620 Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies Equity: Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	1,466	1,725		
Long-term debt 36,425 Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies Equity: Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	491	574		
Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies Equity: 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	92,645	88,121		
Long-term operating lease obligations 13,095 Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies Equity: Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	41,194	40,849		
Long-term finance lease obligations 4,061 Deferred income taxes and other 12,893 Commitments and contingencies Equity: Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	12,909	15,982		
Deferred income taxes and other 12,893 Commitments and contingencies Equity: Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 99,757	3,847	4,750		
Equity: 277 Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	14,370	13,657		
Common stock 277 Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757				
Capital in excess of par value 4,811 Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757				
Retained earnings 85,674 Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	282	283		
Accumulated other comprehensive loss (8,488) Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	3,646	3,485		
Total Walmart shareholders' equity 82,274 Noncontrolling interest 8,483 Total equity 90,757	88,763	92,279		
Noncontrolling interest 8,483 Total equity 90,757	(11,766)	(14,616		
Noncontrolling interest 8,483 Total equity 90,757	80,925	81,431		
Total equity 90,757	6,606	6,073		
	87,531	87,504		
Total liabilities and equity \$ 244,851 \$	\$ 252,496			

Walmart Inc. Condensed Consolidated Statements of Shareholders' Equity (Unaudited)

				Ca	pital in		Accumulate Other	i	Total Walmart		
	Comm	on Stock		Ex	cess of	Retained	Comprehensi	ve	Shareholders'	Noncontrolling	Total
(Amounts in millions)	Shares	Amo	unt	Pa	r Value	Earnings	Loss		Equity	Interest	Equity
Balances as of February 1, 2021	2,821	\$	282	\$	3,646	\$ 88,763	\$ (11,76	6)	\$ 80,925	\$ 6,606	\$ 87,531
Consolidated net income	_		_		_	2,730	-	_	2,730	81	2,811
Other comprehensive income (loss), net of income taxes	_		_		_	_	3,82	0.	3,820	(74)	3,746
Dividends declared (\$2.20 per share)	_		_		_	(6,200)	-	_	(6,200)	_	(6,200)
Purchase of Company stock	(21)		(2)		(112)	(2,718)	-	-	(2,832)	_	(2,832)
Dividends declared to noncontrolling interest	_		_		_	_	-	_	_	(408)	(408)
Sale of subsidiary stock	_		_		18	_	-	_	18	57	75
Other	5		_		(128)	2	-	_	(126)	(5)	(131)
Balances as of April 30, 2021	2,805	\$	280	\$	3,424	\$ 82,577	\$ (7,94	6)	\$ 78,335	\$ 6,257	\$ 84,592
Consolidated net income	_		_		_	4,276		_	4,276	88	4,364
Other comprehensive income (loss), net of income taxes	_		_		_	_	(3	0)	(30)	78	48
Purchase of Company stock	(17)		(2)		(94)	(2,273)	-	_	(2,369)	_	(2,369)
Dividends to noncontrolling interest	_		_		_	_	-	_	_	(10)	(10)
Sale of subsidiary stock	_		_		6	_	-	-	6	171	177
Other	3		_		319	(8)	-	-	311	14	325
Balances as of July 31, 2021	2,791	\$	278	\$	3,655	\$ 84,572	\$ (7,97	6)	\$ 80,529	\$ 6,598	\$ 87,127
Consolidated net income	_		_		_	3,105		_	3,105	27	 3,132
Other comprehensive loss, net of income taxes	_		_		_	_	(51	2)	(512)	(193)	(705)
Dividends	_		_		_	45	-	_	45	_	45
Purchase of Company stock	(14)		(1)		(87)	(2,044)	-	_	(2,132)	_	(2,132)
Dividends to noncontrolling interest	_		_		_	_	-	-	_	(6)	(6)
Sale of subsidiary stock	_		_		922	_	-	_	922	2,057	2,979
Other	1		_		321	(4)	-	-	317	_	317
Balances as of October 31, 2021	2,778	\$	277	\$	4,811	\$ 85,674	\$ (8,48	8)	\$ 82,274	\$ 8,483	\$ 90,757

Walmart Inc. Condensed Consolidated Statements of Shareholders' Equity

(Unaudited)

				Capital in			Accumulated Other	Total Walmart			
		n Stock		Excess of		Retained	Comprehensive	Shareholders'	N	oncontrolling	Total
(Amounts in millions)	Shares	Amoui		Par Value		 arnings	Loss	 Equity		Interest	Equity
Balances as of February 1, 2020	2,832	\$ 2	84	\$ 3,2	17	\$ 83,943	\$ (12,805)	\$	\$	-,	\$ 81,552
Consolidated net income	_		_		_	3,990	_	3,990		84	4,074
Other comprehensive loss, net of income taxes	_		_		_	_	(3,363)	(3,363)		(712)	(4,075)
Dividends declared (\$2.16 per share)	_		_		_	(6,117)	_	(6,117)		_	(6,117)
Purchase of Company stock	(6)		(1)	(2	(6)	(666)	_	(693)		_	(693)
Dividends declared to noncontrolling interest	_		_		_	_	_	_		(359)	(359)
Sale of subsidiary stock	_		_		13	_	_	13		6	19
Other	6		1	(2:	1)	(9)	_	(259)		(32)	(291)
Balances as of April 30, 2020	2,832	\$ 2	84	\$ 2,9	33	\$ 81,141	\$ (16,168)	\$ 68,240	\$	5,870	\$ 74,110
Consolidated net income	_		_		_	6,476	_	6,476		(37)	6,439
Other comprehensive income, net of income taxes	_		_		_	_	384	384		52	436
Dividends to noncontrolling interest	_		_		_	_	_	_		(3)	(3)
Sale of subsidiary stock	_		_		8	_	_	8		3	11
Other	2		(1)	2)6	(3)		 202		2	 204
Balances as of July 31, 2020	2,834	\$ 2	83	\$ 3,1	97	\$ 87,614	\$ (15,784)	\$ 75,310	\$	5,887	\$ 81,197
Consolidated net income	_		_		_	5,135	_	5,135		66	5,201
Other comprehensive income, net of income taxes	_		_		_	_	1,168	1,168		109	1,277
Purchase of Company stock	(4)		_	(7)	(469)	_	(486)		_	(486)
Dividends to noncontrolling interest	_		_		_	_	_	_		(8)	(8)
Sale of subsidiary stock	_		_		5	_	_	5		81	86
Other	1			3	00	(1)		299		(62)	237
Balances as of October 31, 2020	2,831	\$ 2	83	\$ 3,4	35	\$ 92,279	\$ (14,616)	\$ 81,431	\$	6,073	\$ 87,504

Walmart Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

	Nine Months E	ded October 31,		
(Amounts in millions)	2021	2020		
Cash flows from operating activities:				
Consolidated net income	\$ 10,307	\$ 15,714		
Adjustments to reconcile consolidated net income to net cash provided by operating activities:				
Depreciation and amortization	7,952	8,333		
Net unrealized and realized (gains) and losses	1,831	(6,883		
Losses on disposal of business operations	433	1,028		
Deferred income taxes	(1,402)	1,240		
Loss on extinguishment of debt	2,410	_		
Other operating activities	1,057	930		
Changes in certain assets and liabilities, net of effects of acquisitions and dispositions:				
Receivables, net	(842)	165		
Inventories	(12,663)	(8,260		
Accounts payable	7,906	8,553		
Accrued liabilities	(722)	1,790		
Accrued income taxes	24	258		
Net cash provided by operating activities	16,291	22,880		
Cash flows from investing activities:				
Payments for property and equipment	(8,588)	(6,438		
Proceeds from the disposal of property and equipment	290	9		
Proceeds from disposal of certain operations, net of divested cash	7,935	12		
Payments for business acquisitions, net of cash acquired	(248)	(180		
Other investing activities	(919)	_		
Net cash used in investing activities	(1,530)	(6,50°		
Cash flows from financing activities:				
Net change in short-term borrowings	228	(301		
Proceeds from issuance of long-term debt	6,945	`-		
Repayments of long-term debt	(13,010)	(4,132		
Premiums paid to extinguish debt	(2,317)	_		
Dividends paid	(4,627)	(4,582		
Purchase of Company stock	(7,368)	(1,180		
Dividends paid to noncontrolling interest	(20)	(76		
Sale of subsidiary stock	3,231	110		
Other financing activities	(1,175)	(1,179		
Net cash used in financing activities	(18,113)	(11,340		
Effect of exchange rates on cash, cash equivalents and restricted cash	(118)	(170		
Net increase (decrease) in cash, cash equivalents and restricted cash	(3,470)	4,860		
Change in cash and cash equivalents classified as held for sale	1,848	1,00		
Cash, cash equivalents and restricted cash at beginning of year	17,788	9,51:		
Cash, cash equivalents and restricted cash at end of period	\$ 16,166	\$ 14,378		

Walmart Inc

Notes to Condensed Consolidated Financial Statements

Note 1. Summary of Significant Accounting Policies

Basis of Presentation

The Condensed Consolidated Financial Statements of Walmart Inc. and its subsidiaries ("Walmart" or the "Company") and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for the fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. Certain previously reported amounts have been reclassified to conform to the current year presentation. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and do not contain certain information included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021 ("fiscal 2021"). Therefore, the interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K.

The Company's Consolidated Financial Statements are based on a fiscal year ending January 31 for the United States ("U.S.") and Canadian operations. The Company consolidates all other operations generally using a one-month lag based on a calendar year. There were no significant intervening events during the month of October 2021 related to the consolidated operations using a lag that materially affected the Condensed Consolidated Financial Statements.

The Company's business is seasonal to a certain extent due to calendar events and national and religious holidays, as well as weather patterns. Historically, the Company's highest sales volume and operating income have occurred in the fiscal quarter ending January 31.

Use of Estimates

The Condensed Consolidated Financial Statements have been prepared in conformity with GAAP. Those principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Management's estimates and assumptions also affect the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ materially from those estimates.

Investments

Investments in equity and debt securities are recorded in other long-term assets in the Condensed Consolidated Balance Sheets. Changes in fair value of equity securities measured on a recurring basis are recognized in other gains and losses in the Condensed Consolidated Statements of Income. Refer to Note 5 for details. Equity investments without readily determinable fair values are carried at cost and are adjusted for any observable price changes or impairments within other gains and losses in the Condensed Consolidated Statements of Income. Investments in debt securities classified as trading are reported at fair value with interest income recorded in interest income in the Condensed Consolidated Statements of Income. As of October 31, 2021, the Company had \$1.0 billion in debt securities classified as trading.

Indemnification Liabilities

The Company has provided certain indemnifications in connection with its divestitures and has recorded indemnification liabilities equal to the estimated fair value of the obligations upon inception. As of October 31, 2021 and January 31, 2021, the Company had \$0.8 billion and \$0.6 billion, respectively, of certain legal and tax indemnification liabilities recorded within deferred income taxes and other in the Condensed Consolidated Balance Sheets. The maximum amount of potential future payments under these indemnities was \$3.5 billion, based on exchange rates as of October 31, 2021.

Note 2. Net Income Per Common Share

Basic net income per common share attributable to Walmart is based on the weighted-average common shares outstanding during the relevant period. Diluted net income per common share attributable to Walmart is based on the weighted-average common shares outstanding during the relevant period adjusted for the dilutive effect of share-based awards. The Company did not have significant share-based awards outstanding that were anti-dilutive and not included in the calculation of diluted net income per common share attributable to Walmart for the three and nine months ended October 31, 2021 and 2020.

The following table provides a reconciliation of the numerators and denominators used to determine basic and diluted net income per common share attributable to Walmart:

	1	Three Months Er	Nine Months E	Nine Months Ended October 31,				
(Amounts in millions, except per share data)		2021	2020	2021	2020			
Numerator								
Consolidated net income	\$	3,132	\$ 5,201	\$ 10,307	\$ 15,714			
Consolidated net income attributable to noncontrolling interest		(27)	(66)	(196)	(113)			
Consolidated net income attributable to Walmart	\$	3,105	\$ 5,135	\$ 10,111	\$ 15,601			
Denominator								
Weighted-average common shares outstanding, basic		2,785	2,833	2,799	2,832			
Dilutive impact of share-based awards		12	16	14	17			
Weighted-average common shares outstanding, diluted		2,797	2,849	2,813	2,849			
Net income per common share attributable to Walmart								
Basic	\$	1.11	\$ 1.81	\$ 3.61	\$ 5.51			
Diluted		1.11	1.80	3.59	5.48			

Note 3. Accumulated Other Comprehensive Loss

Amounts reclassified from accumulated other comprehensive loss for derivative instruments are generally recorded in interest, net, in the Company's Condensed Consolidated Statements of Income. Amounts for the minimum pension liability, as well as the cumulative translation and any related net investment hedge impacts resulting from a disposition of a business, are recorded in other gains and losses in the Company's Condensed Consolidated Statements of Income. The following tables provide the changes in the composition of total accumulated other comprehensive loss:

	Currency			Minimum Pension	
(Amounts in millions and net of immaterial income taxes)	Translation and Other	Net Investment Hedges	Cash Flow Hedges	Liability	Total
Balances as of February 1, 2021	\$ (10,772)	\$ 1,296	\$ (304)	\$ (1,986)	\$ (11,766)
Other comprehensive loss before reclassifications, net	(225)	(7)	(26)	(1)	(259)
Reclassifications related to business dispositions, net(1)	3,258	(1,195)	30	1,966	4,059
Reclassifications to income, net	_	_	16	4	20
Balances as of April 30, 2021	\$ (7,739)	\$ 94	\$ (284)	\$ (17)	\$ (7,946)
Other comprehensive income (loss) before reclassifications, net	123	_	(193)	(3)	(73)
Reclassifications to income, net	_	_	38	5	43
Balances as of July 31, 2021	\$ (7,616)	\$ 94	\$ (439)	\$ (15)	\$ (7,976)
Other comprehensive income (loss) before reclassifications, net	(330)	_	(181)	4	(507)
Reclassifications to income, net	_	_	(2)	(3)	(5)
Balances as of October 31, 2021	\$ (7,946)	\$ 94	\$ (622)	\$ (14)	\$ (8,488)

⁽¹⁾ Upon closing of the sale of the Company's operations in the U.K. and Japan during the first quarter of fiscal 2022, these amounts were released from accumulated other comprehensive loss, the majority of which was considered in the impairment evaluation when the individual disposal groups met the held for sale classification in fiscal 2021.

(Amounts in millions and net of immaterial income taxes)	Currer Translation a		Net	t Investment Hedges	Cash Flow Hedges	Minimum Pension Liability	Total
Balances as of February 1, 2020	\$	(11,827)	\$	1,517	\$ (539)	\$ (1,956)	\$ (12,805)
Other comprehensive income (loss) before reclassifications, net		(3,256)		157	(295)	(4)	(3,398)
Reclassifications to income, net		_		_	16	19	35
Balances as of April 30, 2020	\$	(15,083)	\$	1,674	\$ (818)	\$ (1,941)	\$ (16,168)
Other comprehensive income (loss) before reclassifications, net		246		(191)	303	(2)	356
Reclassifications to income, net		_		_	10	18	28
Balances as of July 31, 2020	\$	(14,837)	\$	1,483	\$ (505)	\$ (1,925)	\$ (15,784)
Other comprehensive income (loss) before reclassifications, net		1,153		(1)	(13)	(3)	1,136
Reclassifications to income, net		_		_	13	19	32
Balances as of October 31, 2020	\$	(13,684)	\$	1,482	\$ (505)	\$ (1,909)	\$ (14,616)

Note 4. Short-term Borrowings and Long-term Debt

The Company has various committed lines of credit in the U.S. that are used to support its commercial paper program. In April 2021, the Company renewed and extended its existing 364-day revolving credit facility of \$10.0 billion as well as its five-year credit facility of \$5.0 billion. In total, the Company had committed lines of credit in the U.S. of \$15.0 billion at October 31, 2021 and January 31, 2021, all undrawn.

The following table provides the changes in the Company's long-term debt for the nine months ended October 31, 2021:

(Amounts in millions)	Long-term debt due within one year			Long-term debt	Total
Balances as of February 1, 2021	\$	3,115	\$	41,194	\$ 44,309
Proceeds from issuance of long-term debt		_		6,945	6,945
Repayments of long-term debt		(3,010)		(10,000)	(13,010)
Reclassifications of long-term debt		1,461		(1,461)	_
Other		9		(253)	(244)
Balances as of October 31, 2021	\$	1,575	\$	36,425	\$ 38,000

Debt Issuances

Information on significant long-term debt issued during the nine months ended October 31, 2021, for general corporate purposes and certain eligible green initiatives, is as follows:

(Amounts	in	mil	lione)	

Issue Date	Principal Amount	Maturity Date	Fixed vs. Floating	Interest Rate	Net	t Proceeds
September 17, 2021	\$1,250	September 17, 2026	Fixed	1.050%	\$	1,243
September 22, 2021	\$1,250	September 22, 2028	Fixed	1.500%		1,244
September 22, 2021 (1)	\$2,000	September 22, 2031	Fixed	1.800%		1,981
September 22, 2021	\$1,000	September 22, 2041	Fixed	2.500%		994
September 22, 2021	\$1,500	September 22, 2051	Fixed	2.650%		1,483
Total					\$	6,945

⁽¹⁾ Represents a green bond issuance for which an amount equal to the net proceeds is intended to fund certain eligible green investment initiatives through the maturity date of the bond.

These issuances are senior, unsecured notes which rank equally with all other senior, unsecured debt obligations of the Company, and are not convertible or exchangeable. These issuances do not contain any financial covenants and do not restrict the Company's ability to pay dividends or repurchase company stock.

Maturities and Extinguishments

The following table provides details of debt repayments during the nine months ended October 31, 2021:

(Amounts in millions)

Maturity Date	Principal Amount	Fixed vs. Floating	Interest Rate	Repayment(1)
April 15, 2021	\$510	Fixed	4.250%	\$ 510
June 23, 2021	\$750	Floating	Floating	75
June 23, 2021	\$1,750	Fixed	3.125%	1,75
Total repayment of matured debt				3,01
June 26, 2023	\$2,750	Fixed	3.400%	470
October 15, 2023	\$152	Fixed	6.750%	2
July 8, 2024	\$1,500	Fixed	2.850%	510
December 15, 2024	\$1,000	Fixed	2.650%	370
June 26, 2025	\$1,500	Fixed	3.550%	625
July 8, 2026	\$1,250	Fixed	3.050%	451
April 5, 2027	\$483	Fixed	5.875%	110
June 26, 2028	\$2,750	Fixed	3.700%	1,271
July 8, 2029	\$1,250	Fixed	3.250%	517
September 24, 2029	\$500	Fixed	2.375%	181
February 15, 2030	\$588	Fixed	7.550%	119
September 1, 2035	\$1,968	Fixed	5.250%	63
August 15, 2037	\$1,300	Fixed	6.500%	26
April 15, 2038	\$919	Fixed	6.200%	11
June 28, 2038	\$1,500	Fixed	3.950%	92
April 1, 2040	\$751	Fixed	5.625%	14
July 8, 2040	\$378	Fixed	4.875%	10
October 25, 2040	\$519	Fixed	5.000%	12
April 15, 2041	\$918	Fixed	5.625%	30
April 11, 2043	\$709	Fixed	4.000%	29
October 2, 2043	\$269	Fixed	4.750%	3
April 22, 2044	\$502	Fixed	4.300%	17
December 15, 2047	\$1,000	Fixed	3.625%	56
June 29, 2048	\$3,000	Fixed	4.050%	1,31
September 24, 2049	\$1,000	Fixed	2.950%	37
Total repayment of extinguished debt ⁽²⁾				10,000
Total				\$ 13,010

⁽¹⁾ Represents portion of the outstanding principal amount which was repaid during the nine months ended October 31, 2021. (2) Individual repayment amounts may not sum due to rounding.

The Company recorded a \$2.4 billion loss on extinguishment of debt during the three and nine months ended October 31, 2021, which included payment of \$2.3 billion in early extinguishment premiums.

Note 5. Fair Value Measurements

Assets and liabilities recorded at fair value are measured using the fair value hierarchy, which prioritizes the inputs used in measuring fair value. The levels of the fair value hierarchy are:

- Level 1: observable inputs such as quoted prices in active markets;
- Level 2: inputs other than quoted prices in active markets that are either directly or indirectly observable; and
- Level 3: unobservable inputs for which little or no market data exists, therefore requiring the Company to develop its own assumptions.

As described in Note 1, the Company measures the fair value of certain equity investments on a recurring basis in the accompanying Condensed Consolidated Balance Sheets. The fair value of the Company's equity investments measured on a recurring basis is as follows:

(Amounts in millions)	e as of October 1, 2021	Fair Value as of January 31, 2021		
Equity investments measured using Level 1 inputs	\$ 6,124	\$	6,517	
Equity investments measured using Level 2 inputs	6,340		7,905	
Total	\$ 12,464	\$	14,422	

Derivatives

The Company also has derivatives recorded at fair value. Derivative fair values are the estimated amounts the Company would receive or pay upon termination of the related derivative agreements as of the reporting dates. The fair values have been measured using the income approach and Level 2 inputs, which include the relevant interest rate and foreign currency forward curves. As of October 31, 2021 and January 31, 2021, the notional amounts and fair values of these derivatives were as follows:

		October 31, 2021			2021	Januar	y 31,	, 2021
(Amounts in millions)	-	Noti Am	onal ount]	Fair Value	Notional Amount		Fair Value
Receive fixed-rate, pay variable-rate interest rate swaps designated as fair value hedges	5	\$	4,719	\$	91 (1)	\$ 3,250	\$	166 (1)
Receive fixed-rate, pay fixed-rate cross-currency swaps designated as net investment hedges			_		_	1,250		311 (1)
Receive fixed-rate, pay fixed-rate cross-currency swaps designated as cash flow hedges			8,086		(881) ⁽²⁾	5,073		(394) (2)
Total	5	\$	12,805	\$	(790)	\$ 9,573	\$	83

⁽¹⁾ Classified primarily in other long-term assets within the Company's Condensed Consolidated Balance Sheets.

Nonrecurring Fair Value Measurements

In addition to assets and liabilities recorded at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.

As of January 31, 2021, the Company's operations in the U.K. ("Asda") and operations in Japan ("Seiyu") met the held for sale criteria, and as a result the Company recorded non-recurring impairment charges in the fourth quarter of fiscal 2021 as the carrying value of the disposal groups exceeded their fair value, less costs to sell. Upon completing the sales of Asda in February 2021 and Seiyu in March 2021, the Company recorded incremental non-recurring impairment charges of \$0.4 billion in the first quarter of fiscal 2022 within other gains and losses in the Condensed Consolidated Statements of Income. Refer to Note 6. The Company did not have other material assets or liabilities resulting in nonrecurring fair value measurements as of October 31, 2021.

Other Fair Value Disclosures

The Company records cash and cash equivalents, restricted cash, and short-term borrowings at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities.

The Company's long-term debt is also recorded at cost. The fair value is estimated using Level 2 inputs based on the Company's current incremental borrowing rate for similar types of borrowing arrangements. The carrying value and fair value of the Company's long-term debt as of October 31, 2021 and January 31, 2021, are as follows:

	October 31, 2021					January 31, 2021				
(Amounts in millions)	Carrying Value			Fair Value	Carrying Value			Fair Value		
Long-term debt, including amounts due within one year	\$	38,000	\$	44,354	\$	44,309	\$	54,240		

Note 6. Divestitures

During fiscal 2022, the Company completed the following transactions related to the Company's Walmart International segment. After closing these transactions, total assets of the Walmart International segment were \$94.8 billion as of October 31, 2021, as compared to \$109.4 billion as of January 31, 2021.

Asda

In February 2021, the Company completed the divestiture of Asda, the Company's retail operations in the U.K., for net consideration of \$9.6 billion. Upon closing of the transaction, the Company recorded an incremental pre-tax loss of \$0.2 billion

⁽²⁾ Classified primarily in deferred income taxes and other within the Company's Condensed Consolidated Balance Sheets.

in other gains and losses in its Condensed Consolidated Statement of Income in the first quarter of fiscal 2022, primarily related to changes in the net assets of the disposal group, currency exchange rate fluctuations and customary purchase price adjustments upon closing. During the first quarter of fiscal 2022, the Company deconsolidated the financial statements of Asda and recognized its retained investment in Asda as a debt security within other long-term assets and also recognized certain legal and tax indemnity liabilities within deferred income taxes and other on the Condensed Consolidated Balance Sheet.

Seivu

In March 2021, the Company completed the divestiture of Seiyu, the Company's retail operations in Japan, for net consideration of \$1.2 billion. Upon closing of the transaction, the Company recorded an incremental pre-tax loss of \$0.2 billion in other gains and losses in its Condensed Consolidated Statement of Income in the first quarter of fiscal 2022, primarily related to changes in the net assets of the disposal group, currency exchange rate fluctuations and customary purchase price adjustments upon closing. During the first quarter of fiscal 2022, the Company deconsolidated the financial statements of Seiyu and recognized its retained 15 percent ownership interest in Seiyu as an equity investment within other long-term assets on the Condensed Consolidated Balance Sheet.

Note 7. Contingencies

Legal Proceedings

The Company is involved in a number of legal proceedings. The Company has made accruals with respect to these matters, where appropriate, which are reflected in the Company's Condensed Consolidated Financial Statements. For some matters, a liability is not probable or the amount cannot be reasonably estimated and therefore an accrual has not been made. However, where a liability is reasonably possible and may be material, such matters have been disclosed. The Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.

Unless stated otherwise, the matters discussed below, if decided adversely or settled by the Company, individually or in the aggregate, may result in a liability material to the Company's financial condition, results of operations or cash flows.

Opioids Litigation

In December 2017, the United States Judicial Panel on Multidistrict Litigation consolidated numerous lawsuits filed against a wide array of defendants by various plaintiffs, including counties, cities, healthcare providers, Native American tribes, individuals, and third-party payers, asserting claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation is entitled *In re National Prescription Opiate Litigation* (MDL No. 2804) (the "MDL") and is pending in the U.S. District Court for the Northern District of Ohio. The Company is named as a defendant in some of the cases included in this multidistrict litigation. The liability phase of a trial in one of the MDL cases began on October 4, 2021 against a number of parties, including the Company, regarding opioid dispensing claims. On November 23, 2021, the jury found in favor of the plaintiffs as to the liability of all defendants, including the Company intends to appeal this verdict.

Similar cases that name the Company have also been filed in state courts by state, local and tribal governments, health care providers and other plaintiffs. Plaintiffs are seeking compensatory and punitive damages, as well as injunctive relief including abatement. The Company cannot predict the number of such claims that may be filed, but believes it has substantial factual and legal defenses to these claims, and intends to defend the claims vigorously. The Company has also been responding to subpoenas, information requests and investigations from governmental entities related to nationwide controlled substance dispensing and distribution practices involving opioids.

On October 22, 2020, the Company filed a declaratory judgment action in the U.S. District Court for the Eastern District of Texas against the U.S. Department of Justice (the "DOJ") and the U.S. Drug Enforcement Administration, asking a federal court to clarify the roles and responsibilities of pharmacists and pharmacies as to the dispensing and distribution of opioids under the Controlled Substances Act (the "CSA"). The Company's action was dismissed. The Company has appealed this decision to the Fifth Circuit and awaits the court's decision.

On December 22, 2020, the DOJ filed a civil complaint in the U.S. District Court for the District of Delaware alleging that the Company unlawfully dispensed controlled substances from its pharmacies and unlawfully distributed controlled substances to those pharmacies. The complaint alleges that this conduct resulted in violations of the CSA. The DOJ is seeking civil penalties and injunctive relief. The Company filed a motion to dismiss the DOJ complaint on February 22, 2021. The DOJ filed its opposition brief on April 23, 2021 and the Company filed its reply brief on May 24, 2021. On November 19, 2021, the District Court stayed further proceedings in the DOJ complaint pending the decision of the United States Supreme Court in two consolidated cases (not involving Walmart) interpreting the CSA.

In addition, the Company is the subject of two securities class actions alleging violations of the federal securities laws regarding the Company's disclosures with respect to opioids, filed in the U.S. District Court for the District of Delaware on January 20, 2021 and March 5, 2021 purportedly on behalf of a class of investors who acquired Walmart stock from March 30, 2016

through December 22, 2020. Those cases have been consolidated. On October 8, 2021, the defendants filed a motion to dismiss the consolidated securities action. Derivative actions were also filed by two of the Company's shareholders in the U.S. District Court for the District of Delaware on February 9, 2021 and April 16, 2021 alleging breach of fiduciary duties against certain of its current and former directors with respect to oversight of the Company's distribution and dispensing of opioids and also alleging violations of the federal securities laws and other breaches of duty by current directors and two current officers in connection with the Company's opioids disclosures. On September 27, 2021, three shareholders filed a derivative action in the Delaware Court of Chancery alleging that certain members of the current Board and certain former officers breached their fiduciary duties in failing to adequately oversee the Company's prescription opioids business.

The Company cannot reasonably estimate any loss or range of loss that may arise from the various Opioids Litigation and intends to vigorously defend these litigation matters. Accordingly, the Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial position, results of operations or cash flows will not be materially adversely affected.

Asda Equal Value Claims

Prior to the divestiture of Asda, the Company, through its Asda subsidiary, was a defendant in certain equal value claims that began in 2008 and are proceeding before an Employment Tribunal in Manchester in the United Kingdom on behalf of current and former Asda store employees (the "Asda Equal Value Claims"), and further claims may be asserted in the future. Subsequent to the divestiture of Asda in February 2021, the Company will continue to conduct the defense of these claims. While potential liability for these claims remains with Asda, the Company has agreed to provide indemnification with respect to these claims up to a contractually determined amount. The Company cannot predict the number of such claims that may be filed, and cannot reasonably estimate any loss or range of loss that may arise related to these proceedings. Accordingly, the Company can provide no assurance as to the scope and outcomes of these matters.

Note 8. Segments and Disaggregated Revenue

Segments

The Company is engaged in the operation of retail, wholesale, eCommerce websites and other units located throughout the U.S., Africa, Canada, Central America, Chile, China, India and Mexico. The Company's operations are conducted in three reportable segments: Walmart U.S., Walmart International and Sam's Club. The Company defines its segments as those operations whose results the chief operating decision maker ("CODM") regularly reviews to analyze performance and allocate resources. The Company sells similar individual products and services in each of its segments. It is impractical to segregate and identify revenues for each of these individual products and services.

The Walmart U.S. segment includes the Company's mass merchandising concept in the U.S., as well as eCommerce and omni-channel initiatives. The Walmart International segment consists of the Company's operations outside of the U.S., as well as eCommerce and omni-channel initiatives. The Sam's Club segment includes the warehouse membership clubs in the U.S., as well as samsclub.com and omni-channel initiatives. Corporate and support consists of corporate overhead and other items not allocated to any of the Company's segments.

The Company measures the results of its segments using, among other measures, each segment's net sales and operating income, which includes certain corporate overhead allocations. From time to time, the Company revises the measurement of each segment's operating income and other measures, including any corporate overhead allocations, as determined by the information regularly reviewed by its CODM. When the measurement of a segment significantly changes, previous period amounts and balances are reclassified to be comparable to the current period's presentation.

Net sales by segment are as follows:

	Three Months E	nded (October 31,	Nine Months En	ided O	ctober 31,
(Amounts in millions) Net sales:	 2021		2020	 2021		2020
Walmart U.S.	\$ 96,609	\$	88,353	\$ 287,968	\$	270,378
Walmart International	23,627		29,554	73,962		86,487
Sam's Club	18,971		15,845	54,307		47,383
Net sales	\$ 139,207	\$	133,752	\$ 416,237	\$	404,248

Operating income by segment, as well as operating loss for corporate and support, interest, net, loss on extinguishment of debt and other gains and losses are as follows:

	Three Months En	Nine Months I	ber 31,		
(Amounts in millions)	2021	2020	2021		2020
Operating income (loss):	 				<u> </u>
Walmart U.S.	\$ 4,860	\$ 4,589	\$ 16,404	\$	13,948
Walmart International	871	1,078	2,926		2,696
Sam's Club	475	431	1,710		1,517
Corporate and support	(414)	(320)	(985)		(1,100)
Operating income	5,792	5,778	20,055		17,061
Interest, net	442	516	1,456		1,700
Loss on extinguishment of debt	2,410	_	2,410		_
Other (gains) and losses	(1,207)	(1,853)	2,275		(5,796)
Income before income taxes	\$ 4,147	\$ 7,115	\$ 13,914	\$	21,157

Disaggregated Revenues

In the following tables, segment net sales are disaggregated by either merchandise category or by market. From time to time, the Company revises the assignment of net sales of a particular item to a merchandise category. When the assignment changes, previous period amounts are reclassified to be comparable to the current period's presentation.

In addition, net sales related to eCommerce are provided for each segment, which include omni-channel sales, where a customer initiates an order digitally and the order is fulfilled through a store or club.

(Amounts in millions)		Three Months E	nded Octo	ber 31,		Nine Months Ended October 31,			
Walmart U.S. net sales by merchandise category	2021		2020		2021			2020	
Grocery	\$	55,560	\$	50,683	\$	161,600	\$	155,149	
General merchandise		28,544		26,927		90,858		84,075	
Health and wellness		11,030		9,806		31,480		28,560	
Other categories		1,475		937		4,030		2,594	
Total	\$	96,609	\$	88,353	\$	287,968	\$	270,378	

Of Walmart U.S.'s total net sales, approximately \$11.1 billion and \$10.3 billion related to eCommerce for the three months ended October 31, 2021 and 2020, respectively, and approximately \$33.6 billion and \$29.1 billion related to eCommerce for the nine months ended October 31, 2021 and 2020, respectively.

(Amounts in millions)	Three Months E	nded Oct	ober 31,		tober 31,		
Walmart International net sales by market	2021		2020		2021		2020
Mexico and Central America	\$ 8,718	\$	7,429	\$	25,706	\$	23,133
United Kingdom	_		7,249		3,811		21,079
Canada	5,507		4,969		15,847		14,383
China	3,538		2,787		10,313		8,735
Other	5,864		7,120		18,285		19,157
Total	\$ 23,627	\$	29,554	\$	73,962	\$	86,487

Of Walmart International's total net sales, approximately \$4.3 billion related to eCommerce for each of the three months ended October 31, 2021 and 2020, respectively, and approximately \$12.7 billion and \$10.5 billion related to eCommerce for the nine months ended October 31, 2021 and 2020, respectively.

(Amounts in millions)	Three Months E	nded October 31,	Nine Months Ended October 31,			
Sam's Club net sales by merchandise category	2021	2020	2021		2020	
Grocery and consumables	\$ 12,335	\$ 10,450	\$ 35,018	\$	31,526	
Fuel, tobacco and other categories	2,932	1,942	8,047		6,023	
Home and apparel	1,976	1,693	6,252		4,926	
Health and wellness	1,037	1,017	2,934		2,849	
Technology, office and entertainment	691	743	2,056		2,059	
Total	\$ 18,971	\$ 15,845	\$ 54,307	\$	47,383	

Of Sam's Club's total net sales, approximately \$1.7 billion and \$1.3 billion related to eCommerce for the three months ended October 31, 2021 and 2020, respectively, and approximately \$4.9 billion and \$3.7 billion related to eCommerce for the nine months ended October 31, 2021 and 2020, respectively.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

This discussion, which presents Walmart Inc.'s ("Walmart," the "Company," "our," or "we") results for periods occurring in the fiscal year ending January 31, 2021 ("fiscal 2021"), should be read in conjunction with our Condensed Consolidated Financial Statements as of and for the three and nine months ended October 31, 2021, and the accompanying notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as our Consolidated Financial Statements as of and for the year ended January 31, 2021, the accompanying notes and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K for the year ended January 31, 2021.

We intend for this discussion to provide the reader with information that will assist in understanding our financial statements, the changes in certain key items in those financial statements from period to period and the primary factors that accounted for those changes. We also discuss certain performance metrics that management uses to assess the Company's performance. Additionally, the discussion provides information about the financial results of each of the three segments of our business to provide a better understanding of how each of those segments and its results of operations affect the financial condition and results of operations of the Company as a whole.

Throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations, we discuss segment operating income, comparable store and club sales and other measures. Management measures the results of the Company's segments using each segment's operating income, including certain corporate overhead allocations, as well as other measures. From time to time, we revise the measurement of each segment's operating income and other measures as determined by the information regularly reviewed by our chief operating decision maker.

Comparable store and club sales, or comparable sales, is a metric that indicates the performance of our existing stores and clubs by measuring the change in sales for such stores and clubs, including eCommerce sales, for a particular period from the corresponding prior year period. Walmart's definition of comparable sales includes sales from stores and clubs open for the previous 12 months, including remodels, relocations, expansions and conversions, as well as eCommerce sales. We measure the eCommerce sales impact by including all sales initiated digitally, including omni-channel transactions which are fulfilled through our stores and clubs. Sales at a store that has changed in format are excluded from comparable sales when the conversion of that store is accompanied by a relocation or expansion that results in a change in the store's retail square feet of more than five percent. Sales related to divested businesses are excluded from comparable sales, and sales related to acquisitions are excluded until such acquisitions have been owned for 12 months. Comparable sales are also referred to as "same-store" sales by others within the retail industry. The method of calculating comparable sales varies across the retail industry. As a result, our calculation of comparable sales is not necessarily comparable to similarly titled measures reported by other companies.

In discussing our operating results, the term currency exchange rates refers to the currency exchange rates we use to convert the operating results for countries where the functional currency is not the U.S. dollar into U.S. dollars. We calculate the effect of changes in currency exchange rates as the difference between current period activity translated using the current period's currency exchange rates and the comparable prior year period's currency exchange rates. Additionally, no currency exchange rate fluctuations are calculated for non-USD acquisitions until owned for 12 months. Throughout our discussion, we refer to the results of this calculation as the impact of currency exchange rate fluctuations. Volatility in currency exchange rates may impact the results, including net sales and operating income, of the Company and the Walmart International segment in the future.

Each of our segments contributes to the Company's operating results differently. Each, however, has generally maintained a consistent contribution rate to the Company's net sales and operating income in recent years other than minor changes to the contribution rate for the Walmart International segment due to fluctuations in currency exchange rates. Consistent with our strategy to strengthen our Walmart International portfolio for the long-term, we completed the following actions during the nine months ended October 31, 2021:

- Completed the sale of Asda, our retail business in the U.K., for net consideration of \$9.6 billion in February 2021. During the first quarter of fiscal 2022, we recognized an incremental non-cash loss of \$0.2 billion, after tax, primarily due to changes in the net assets of the disposal group, currency exchange rate fluctuations and customary purchase price adjustments upon closing.
- Completed the sale of Seiyu, our retail business in Japan, for net consideration of \$1.2 billion in March 2021. During the first quarter of fiscal 2022, we recognized an incremental non-cash loss of \$0.2 billion, after tax, primarily due to changes in the net assets of the disposal group, currency exchange rate fluctuations and customary purchase price adjustments upon closing.

We operate in the highly competitive omni-channel retail industry in all of the markets we serve. We face strong sales competition from other discount, department, drug, dollar, variety and specialty stores, warehouse clubs and supermarkets, as well as eCommerce businesses. Many of these competitors are national, regional or international chains or have a national or international omni-channel or eCommerce presence. We compete with a number of companies for attracting and retaining quality employees ("associates"). We, along with other retail companies, are influenced by a number of factors including, but not limited to: catastrophic events, weather and other risks related to climate change, global health epidemics, including the ongoing COVID-19 pandemic, competitive pressures, consumer disposable income, consumer debt levels and buying patterns, consumer credit availability, supply chain disruptions, cost and availability of goods, currency exchange rate fluctuations, customer preferences, deflation, inflation, fuel and energy prices, general economic conditions, insurance costs, interest rates, labor availability and costs, tax rates, the imposition of tariffs, cybersecurity attacks and unemployment. Further information on the factors that can affect our operating results and on certain risks to our Company and an investment in our securities can be found herein under "Item 5. Other Information."

We expect continued uncertainty in our business and the global economy due to the duration and intensity of the COVID—19 pandemic; the duration and extent of economic stimulus measures; timing and effectiveness of global vaccines, as well as potential impacts of any related vaccine mandates on our workforce; supply chain disruptions; and volatility in employment trends and consumer confidence which may impact our results. For a detailed discussion on results of operations by reportable segment, refer to "Results of Operations" below.

Company Performance Metrics

We are committed to helping customers save money and live better through everyday low prices, supported by everyday low costs. At times, we adjust our business strategies to maintain and strengthen our competitive positions in the countries in which we operate. We define our financial framework as:

- · strong, efficient growth;
- · consistent operating discipline; and
- · strategic capital allocation.

As we execute on this financial framework, we believe our returns on capital will improve over time.

Strong, Efficient Growth

Our objective of prioritizing strong, efficient growth means we will focus on the most productive growth opportunities, increasing comparable store and club sales, accelerating eCommerce sales growth and expansion of omni-channel initiatives while slowing the rate of growth of new stores and clubs. At times, we make strategic investments which are focused on the long-term growth of the Company.

Comparable sales is a metric that indicates the performance of our existing stores and clubs by measuring the change in sales for such stores and clubs, including eCommerce sales, for a particular period over the corresponding period in the previous year. The retail industry generally reports comparable sales using the retail calendar (also known as the 4-5-4 calendar). To be consistent with the retail industry, we provide comparable sales using the retail calendar in our quarterly earnings releases. However, when we discuss our comparable sales below, we are referring to our calendar comparable sales calculated using our fiscal calendar, which may result in differences when compared to comparable sales using the retail calendar.

Calendar comparable sales, as well as the impact of fuel, for the three and nine months ended October 31, 2021 and 2020, were as follows:

	Three Months Ended October 31,					Nine Months Ende	led October 31,		
	2021	2020	2021	2020	2021 2020		2021	2020	
	With Fu	iel	Fuel Impact		With Fu	iel	Fuel Impact		
Walmart U.S.	9.4 %	6.6 %	0.4 %	(0.1)%	6.7 %	8.9 %	0.4 %	(0.2)%	
Sam's Club	19.6 %	8.3 %	5.9 %	(3.3)%	14.6 %	8.9 %	5.4 %	(3.8)%	
Total U.S.	11.0 %	6.8 %	1.3 %	(0.6)%	7.9 %	8.9 %	1.2 %	(0.7)%	

Comparable sales in the U.S., including fuel, increased 11.0% and 7.9% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The Walmart U.S. segment had comparable sales growth of 9.4% and 6.7% for the three and nine months ended October 31, 2021, respectively, driven by growth in transactions and average ticket, which includes strong consumer spending from government stimulus and some higher inflation impacts in certain merchandise categories compared to recent years. In the first quarter of fiscal 2022, average ticket increased while transactions decreased as customers consolidated shopping trips and purchased larger baskets. Transaction growth turned positive in April 2021 and continued with strong growth through the second and third quarters of fiscal 2022 as customers' pre-pandemic behaviors largely resumed. The Walmart U.S. segment's eCommerce sales grew at a slower rate than total comparable sales which negatively contributed approximately 0.1% to comparable sales for the three months ended October 31,

2021 as customers shifted toward more in-store shopping as compared to the same period in the previous year. For the nine months ended October 31, 2021, eCommerce sales positively contributed approximately 1.3% to comparable sales, primarily driven by store pick-up and delivery.

Comparable sales at the Sam's Club segment increased 19.6% and 14.6% for the three and nine months ended October 31, 2021, respectively. Growth in comparable sales benefited from growth in transactions and average ticket and was aided by consumer spending due to government stimulus, and also includes some higher inflation impacts in certain merchandise categories compared to recent years. The growth in comparable sales was partially offset by our decision to remove tobacco from certain club locations. The Sam's Club segment's eCommerce sales positively contributed approximately 1.1% and 1.7% to comparable sales for the three and nine months ended October 31, 2021, respectively.

Consistent Operating Discipline

We operate with discipline by managing expenses and optimizing the efficiency of how we work and creating an environment in which we have sustainable lowest cost to serve. We invest in technology and process improvements to increase productivity, manage inventory, and reduce costs. We measure operating discipline through expense leverage, which we define as net sales growing at a faster rate than operating, selling, general and administrative ("operating") expenses.

	Three Months Ended October 31,			Nine Months Ended October 31,				
(Amounts in millions)	 2021	2020		2021		2020		
Net sales	\$ 139,207	\$ 133,752	\$	416,237	\$	404,248		
Percentage change from comparable period	4.1 %	5.3 %		3.0 %		6.6 %		
Operating, selling, general and administrative expenses	\$ 29,710	\$ 28,591	\$	86,350	\$	84,957		
Percentage change from comparable period	3.9 %	4.4 %		1.6 %		5.9 %		
Operating, selling, general and administrative expenses as a percentage of net sales	21.3 %	21.4 %		20.7 %		21.0 %		

Operating expenses as a percentage of net sales was relatively flat for the three months ended October 31, 2021, which benefited from growth in net sales and \$0.2 billion of lower incremental COVID-19 related costs as compared to the same period in the prior year, offset by increased wage investments primarily in the Walmart U.S. segment. Operating expenses as a percentage of net sales decreased 27 basis points for the nine months ended October 31, 2021, primarily driven by net sales growth and lower incremental COVID-19 related costs of \$2.0 billion as compared to the same period in the prior year, partially offset by increased wage investments primarily in the Walmart U.S. segment.

Strategic Capital Allocation

Our strategy includes improving our customer-facing initiatives in stores and clubs and creating a seamless omni-channel experience for our customers. As such, we are allocating more capital to supply chain, customer-facing initiatives, technology and store remodels, and less to new store and club openings. The following table provides additional detail:

(Amounts in millions)	Nine Months Ended October 31,			
Allocation of Capital Expenditures	2021 202			2020
Supply chain, customer-facing initiatives and technology	\$	4,408	\$	3,316
Store and club remodels		2,375		1,531
New stores and clubs, including expansions and relocations		112		64
Total U.S.		6,895		4,911
Walmart International		1,693		1,527
Total Capital Expenditures	\$	8,588	\$	6,438

Returns

As we execute our financial framework, we believe our return on capital will improve over time. We measure return on capital with our return on investment and free cash flow metrics. In addition, we provide returns in the form of share repurchases and dividends, which are discussed in the <u>Liquidity and Capital Resources</u> section.

Return on Assets and Return on Investment

We include Return on Assets ("ROA"), the most directly comparable measure based on our financial statements presented in accordance with generally accepted accounting principles in the U.S. ("GAAP"), and Return on Investment ("ROI") as metrics to assess returns on assets. While ROI is considered a non-GAAP financial measure, management believes ROI is a meaningful metric to share with investors because it helps investors assess how effectively Walmart is deploying its assets. Trends in ROI can fluctuate over time as management balances long-term strategic initiatives with possible short-term impacts. ROA was 3.3% and 8.2% for the trailing twelve months ended October 31, 2021 and 2020, respectively. The decrease in ROA was primarily due to net fair value changes in our equity instruments as well as the losses on divestiture of our operations in the

U.K. and Japan, partially offset by the increase in operating income. ROI was 14.5% and 13.7% for the trailing twelve months ended October 31, 2021 and 2020. The increase in ROI was primarily due to the increase in operating income.

We define ROI as adjusted operating income (operating income plus interest income, depreciation and amortization, and rent expense) for the trailing 12 months divided by average invested capital during that period. We consider average invested capital to be the average of our beginning and ending total assets, plus average accumulated depreciation and amortization, less average accounts payable and average accrued liabilities for that period.

Our calculation of ROI is considered a non-GAAP financial measure because we calculate ROI using financial measures that exclude and include amounts that are included and excluded in the most directly comparable GAAP financial measure. For example, we exclude the impact of depreciation and amortization from our reported operating income in calculating the numerator of our calculation of ROI. As mentioned above, we consider ROA to be the financial measure computed in accordance with GAAP most directly comparable to our calculation of ROI. ROI differs from ROA (which is consolidated net income for the period divided by average total assets for the period) because ROI: adjusts operating income to exclude certain expense items and adds interest income; and adjusts total assets for the impact of accumulated depreciation and amortization, accounts payable and accrued liabilities to arrive at total invested capital. Because of the adjustments mentioned above, we believe ROI more accurately measures how we are deploying our key assets and is more meaningful to investors than ROA. Although ROI is a standard financial measure, numerous methods exist for calculating a company's ROI. As a result, the method used by management to calculate our ROI may differ from the methods used by other companies to calculate their ROI.

The calculation of ROA and ROI, along with a reconciliation of ROI to the calculation of ROA, the most comparable GAAP financial measure, is as follows:

	For th	For the Trailing Twelve Months Ending October 31,						
(Amounts in millions)		2021		2020				
CALCULATION OF RETURN ON ASSETS								
Numerator								
Consolidated net income	\$	8,299	\$	20,008				
Denominator								
Average total assets ⁽¹⁾	<u>\$</u>	247,857	\$	245,347				
Return on assets (ROA)		3.3 %		8.2 %				
			-					
CALCULATION OF RETURN ON INVESTMENT								
Numerator								
Operating income	\$	25,542	\$	22,383				
+ Interest income		141		132				
+ Depreciation and amortization		10,771		11,161				
+ Rent		2,360		2,646				
= ROI operating income	\$	38,814	\$	36,322				
Denominator								
Average total assets ⁽¹⁾	\$	247,857	\$	245,347				
+ Average accumulated depreciation and amortization(1)		99,872		95,637				
- Average accounts payable ⁽¹⁾		55,654		51,951				
- Average accrued liabilities ⁽¹⁾		24,735		22,984				
= Average invested capital	\$	267,340	\$	266,049				
Return on investment (ROI)		14.5 %		13.7 %				

⁽¹⁾ The average is based on the addition of the account balance at the end of the current period to the account balance at the end of the prior period and dividing by 2.

	As of October 31,						
	 2021		2020		2019		
Certain Balance Sheet Data							
Total assets	\$ 244,851	\$	250,863	\$	239,830		
Accumulated depreciation and amortization	100,168		99,576		91,697		
Accounts payable	57,156		54,152		49,750		
Accrued liabilities	24,474		24,995		20,973		

Free Cash Flow

Free cash flow is considered a non-GAAP financial measure. Management believes, however, that free cash flow, which measures our ability to generate cash from our business operations, is an important financial measure for use in evaluating the Company's financial performance. Free cash flow should be considered in addition to, rather than as a substitute for, consolidated net income as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. See <u>Liquidity and Capital Resources</u> for discussions of GAAP metrics including net cash provided by operating activities, net cash used in investing activities and net cash used in financing activities.

We define free cash flow as net cash provided by operating activities in a period minus payments for property and equipment made in that period. We had net cash provided by operating activities of \$16.3 billion for the nine months ended October 31, 2021, which decreased when compared to \$22.9 billion for the nine months ended October 31, 2020 primarily due to an increase in inventory purchases to support strong sales and lapping the impact of accelerated inventory sell-through in fiscal 2021, as well as timing and payment of wages. We generated free cash flow of \$7.7 billion for the nine months ended October 31, 2021, which decreased when compared to \$16.4 billion for the nine months ended October 31, 2020 due to the same reasons as the decrease in net cash provided by operating activities, as well as \$2.2 billion in increased capital expenditures.

Walmart's definition of free cash flow is limited in that it does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as a measure that provides supplemental information to our Condensed Consolidated Statements of Cash Flows.

Although other companies report their free cash flow, numerous methods may exist for calculating a company's free cash flow. As a result, the method used by management to calculate our free cash flow may differ from the methods used by other companies to calculate their free cash flow.

The following table sets forth a reconciliation of free cash flow, a non-GAAP financial measure, to net cash provided by operating activities, which we believe to be the GAAP financial measure most directly comparable to free cash flow, as well as information regarding net cash used in investing activities and net cash used in financing activities.

	Nine Months Ended October 31,						
(Amounts in millions)		2021		2020			
Net cash provided by operating activities	\$	16,291	\$	22,880			
Payments for property and equipment		(8,588)		(6,438)			
Free cash flow	\$	7,703	\$	16,442			
			-				
Net cash used in investing activities ⁽¹⁾	\$	(1,530)	\$	(6,507)			
Net cash used in financing activities		(18,113)		(11,340)			

^{(1) &}quot;Net cash used in investing activities" includes payments for property and equipment, which is also included in our computation of free cash flow.

Results of Operations

Consolidated Results of Operations

	Three Months Ended October 31,				Nine Months Ended October 31,				
(Amounts in millions, except unit counts)	2021		2020		2021		2020		
Total revenues	\$ 140,525	\$	134,708	\$	419,883	\$	407,072		
Percentage change from comparable period	4.3%		5.2%		3.1 %		6.5%		
Net sales	\$ 139,207	\$	133,752	\$	416,237	\$	404,248		
Percentage change from comparable period	4.1%		5.3%		3.0 %		6.6%		
Total U.S. calendar comparable sales increase	11.0%		6.8%		7.9 %		8.9%		
Gross profit margin as a percentage of net sales	24.6%		25.0%		24.7 %		24.5%		
Operating income	\$ 5,792	\$	5,778	\$	20,055	\$	17,061		
Operating income as a percentage of net sales	4.2%		4.3%		4.8 %		4.2%		
Loss on extinguishment of debt	\$ 2,410	\$	_	\$	2,410	\$	_		
Other (gains) and losses	\$ (1,207)	\$	(1,853)	\$	2,275	\$	(5,796)		
Consolidated net income	\$ 3,132	\$	5,201	\$	10,307	\$	15,714		
Unit counts at period end	10,566		11,510		10,566		11,510		
Retail square feet at period end	1,065		1,128		1,065		1,128		

Our total revenues, which are mostly comprised of net sales, but also include membership and other income, increased \$5.8 billion or 4.3% and \$12.8 billion or 3.1% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The increases in revenues were primarily due to strong positive comparable sales for the Walmart U.S. and Sam's Club segments which benefited from strong U.S. consumer spending and some inflation, along with positive comparable sales in the majority of our remaining international markets. These increases were partially offset by net sales decreases of \$9.4 billion and \$22.4 billion for the three and nine months ended October 31, 2021, respectively, primarily related to the divestiture of our operations in the U.K. and Japan, which closed in February 2021 and March 2021, respectively. Net sales also benefited from a \$1.3 billion and \$4.7 billion positive impact of fluctuations in currency exchange rates for the three and nine months ended October 31, 2021, respectively.

Gross profit as a percentage of net sales ("gross profit rate") decreased 42 basis points for the three months ended October 31, 2021 when compared to the same period in the previous fiscal year, primarily due to higher supply chain costs and fuel mix in the Walmart U.S. and Sam's Club segments. These decreases were partially offset by benefits in the Walmart U.S. segment related to lower markdowns, price management, and growth in our advertising business.

Gross profit rate increased 15 basis points for the nine months ended October 31, 2021 when compared to the same period in the previous fiscal year. The decrease for the three months ended October 31, 2021 was more than offset by increases in the first quarter of fiscal 2022 primarily driven by mix shifts into general merchandise in the Walmart U.S. segment, due in part to government stimulus spending, lower markdowns and lapping last year's COVID-19 related mix shifts into lower margin categories such as food and consumables.

Operating expenses as a percentage of net sales was relatively flat for the three months ended October 31, 2021, which benefited from growth in net sales and \$0.2 billion of lower incremental COVID-19 related costs as compared to the same period in the prior year, offset by increased wage investments primarily in the Walmart U.S. segment. Operating expenses as a percentage of net sales decreased 27 basis points for the nine months ended October 31, 2021, primarily driven by net sales growth and lower incremental COVID-19 related costs of \$2.0 billion as compared to the same period in the prior year, partially offset by increased wage investments primarily in the Walmart U.S. segment.

Loss on extinguishment of debt was \$2.4 billion for both the three and nine months ended October 31, 2021, due to the early retirement of certain higher rate long-term debt to reduce interest expense in future periods.

Other gains and losses for the three months ended October 31, 2021 consisted of a net gain of \$1.2 billion primarily associated with the fair value changes of our equity investments. Other gains and losses for the nine months ended October 31, 2021 consisted of a net loss of \$2.3 billion which primarily reflects \$1.8 billion in net losses associated with the fair value changes of our equity investments, as well as \$0.4 billion in incremental losses associated with the divestiture of our operations in the U.K. and Japan upon closing of the transactions during the first quarter of fiscal 2022. For the three and nine months ended October 31, 2020, other gains and losses consisted of a net gain of \$1.9 billion and \$5.8 billion, respectively, primarily representing the fair value changes of our equity investments and the loss on sale of Walmart Argentina.

Our effective income tax rate was 24.5% and 25.9% for the three and nine months ended October 31, 2021, respectively, compared to 26.9% and 25.7% for the same periods in the previous fiscal year. The decrease in effective tax rate for the three months ended October 31, 2021 is primarily due to the loss on sale of Walmart Argentina recorded in the third quarter of fiscal 2021, as it provided minimal realizable tax benefit. Our effective income tax rate may fluctuate from quarter to quarter as a result of factors including changes in our assessment of certain tax contingencies, valuation allowances, changes in tax law,

outcomes of administrative audits, the impact of discrete items and the mix and size of earnings among our U.S. operations and international operations, which are subject to statutory rates that may be different than the U.S. statutory rate.

As a result of the factors discussed above, consolidated net income decreased \$2.1 billion and \$5.4 billion for the three and nine months ended October 31, 2021 respectively, when compared to the same periods in the previous fiscal year. Accordingly, diluted net income per common share attributable to Walmart was \$1.11 and \$3.59 for the three and nine months ended October 31, 2021, respectively, which represents respective decreases of \$0.69 and \$1.89, when compared to the same periods in the previous fiscal year.

Walmart U.S. Segment

	Three Months Ended October 31,				Nine Months Ended October 31,			
(Amounts in millions, except unit counts)		2021		2020		2021		2020
Net sales	\$	96,609	\$	88,353	\$	287,968	\$	270,378
Percentage change from comparable period		9.3 %		6.2 %		6.5 %		8.7 %
Calendar comparable sales increase		9.4 %		6.6 %		6.7 %		8.9 %
Operating income	\$	4,860	\$	4,589	\$	16,404	\$	13,948
Operating income as a percentage of net sales		5.0 %		5.2 %		5.7 %		5.2 %
Unit counts at period end		4,742		4,748		4,742		4,748
Retail square feet at period end		703		703		703		703

Net sales for the Walmart U.S. segment increased \$8.3 billion or 9.3% and \$17.6 billion or 6.5% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The increases were due to comparable sales of 9.4% and 6.7% for the three and nine months ended October 31, 2021, respectively, driven by growth in transactions and average ticket, which includes strong consumer spending from government stimulus and some higher inflation impacts in certain merchandise categories compared to recent years. In the first quarter of fiscal 2022, average ticket increased while transactions decreased as customers consolidated shopping trips and purchased larger baskets. Transaction growth turned positive in April 2021 and continued with strong growth through the second and third quarters of fiscal 2022 as customers' pre-pandemic behaviors largely resumed. The Walmart U.S. segment's eCommerce sales grew at a slower rate than total comparable sales which negatively contributed approximately 0.1% to comparable sales for the three months ended October 31, 2021 as customers shifted toward more in-store shopping as compared to the same period in the previous year. For the nine months ended, eCommerce sales positively contributed approximately 1.3% to comparable sales, primarily driven by store pick-up and delivery.

Gross profit rate decreased 12 basis points for the three months ended October 31, 2021 when compared to the same period in the previous fiscal year, primarily driven by higher supply chain costs and fuel mix, partially offset by lower markdowns, price management, and growth in our advertising business. For the nine months ended October 31, 2021, gross profit rate increased 50 basis points due primarily to shifts into general merchandise due in part to government stimulus spending and lapping last year's COVID-related mix shifts into food and consumables in the first quarter of fiscal 2021. Gross profit rate was also impacted by lower markdowns, lapping the temporary closures of our Auto Care Centers and Vision centers, price management, and growth in our advertising business, partially offset by increased supply chain costs.

Operating expenses as a percentage of net sales increased 20 basis points for the three months ended October 31, 2021 when compared to the same period in the previous fiscal year, primarily driven by increased wage investments, partially offset by strong sales growth and \$0.1 billion of lower incremental COVID-19 costs. Operating expenses as a percentage of net sales were relatively flat for the nine months ended October 31, 2021 when compared to the same period in the previous fiscal year, which benefited from strong sales, lower incremental COVID-19 costs of \$1.5 billion and lapping a \$0.4 billion business restructuring charge in the second quarter of fiscal 2021, partially offset by increased investments in wages.

As a result of the factors discussed above, operating income increased \$0.3 billion and \$2.5 billion for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year.

Walmart International Segment

	Three Months Ended October 31,			Nine Months Ended October 31,		
(Amounts in millions, except unit counts)	 2021		2020	2021		2020
Net sales	\$ 23,627	\$	29,554	\$ 73,962	\$	86,487
Percentage change from comparable period	(20.1)%		1.3 %	(14.5)%		(0.7)%
Operating income	\$ 871	\$	1,078	\$ 2,926	\$	2,696
Operating income as a percentage of net sales	3.7 %		3.6 %	4.0 %		3.1 %
Unit counts at period end	5,224		6,163	5,224		6,163
Retail square feet at period end	282		345	282		345

Net sales for the Walmart International segment decreased \$5.9 billion or 20.1% and \$12.5 billion or 14.5% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The reduction in net sales was due to decreases of \$9.4 billion and \$22.4 billion for the three and nine months ended October 31, 2021, respectively, primarily related to the divestiture of Asda and Seiyu during the first quarter of fiscal 2022. The decreases were partially offset by positive net sales growth in the majority of our remaining markets. Net sales for the three and nine months ended October 31, 2021 included positive fluctuations in currency exchange rates of \$1.3 billion and \$4.7 billion, respectively.

Gross profit rate decreased 86 basis points for the three months ended October 31, 2021 when compared to the same period in the previous fiscal year, primarily driven by shifts into lower margin formats. The divested markets also negatively impacted our gross profit rate. Gross profit rate decreased 38 basis points for the nine months ended October 31, 2021, when compared to the same period in the previous fiscal year primarily driven by shifts into lower margin formats and the decrease related to our divested markets, partially offset by benefits in the first quarter of fiscal 2022 related to mix shifts into higher margin categories and lower markdowns.

Operating expenses as a percentage of net sales decreased 10 and 62 basis points for the three and nine months ended October 31, 2021, respectively when compared to the same periods in the previous fiscal year, primarily due to lower incremental COVID-19 related costs and impacts from the divested markets. Additionally, operating expenses as a percentage of net sales for the nine months ended October 31, 2021 benefited from depreciation and amortization expense not having been recorded for our operations in the U.K. and Japan subsequent to their held for sale classification at the end of fiscal 2021 and prior to closing during the first quarter of fiscal 2022.

Operating income for the three and nine months ended October 31, 2021 included positive fluctuations in currency exchange rates of \$0.1 billion and \$0.3 billion, respectively. As a result of the factors discussed above, operating income decreased \$0.2 billion and increased \$0.2 billion for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year.

Sam's Club Segment

	Three Months Ended Octo	ber 31,	Nine Months Ended October 31,			
(Amounts in millions, except unit counts)	 2021	2020	2021	2020		
Including Fuel	 					
Net sales	\$ 18,971 \$	15,845 \$	54,307 \$	47,383		
Percentage change from comparable period	19.7 %	8.3 %	14.6 %	8.9 %		
Calendar comparable sales increase	19.6 %	8.3 %	14.6 %	8.9 %		
Operating income	\$ 475 \$	431 \$	1,710 \$	1,517		
Operating income as a percentage of net sales	2.5 %	2.7 %	3.1 %	3.2 %		
Unit counts at period end	600	599	600	599		
Retail square feet at period end	80	80	80	80		
Excluding Fuel (1)						
Net sales	\$ 16,614 \$	14,596 \$	47,988 \$	43,929		
Percentage change from comparable period	13.8 %	11.6 %	9.2 %	12.7 %		
Operating income	\$ 368 \$	358 \$	1,473 \$	1,283		
Operating income as a percentage of net sales	2.2 %	2.5 %	3.1 %	2.9 %		

⁽¹⁾ We believe the "Excluding Fuel" information is useful to investors because it permits investors to understand the effect of the Sam's Club segment's fuel sales on its results of operations, which are impacted by the volatility of fuel prices. Volatility in fuel prices may continue to impact the operating results of the Sam's Club segment in the future.

Net sales for the Sam's Club segment increased \$3.1 billion or 19.7% and \$6.9 billion or 14.6% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The increases were primarily due to comparable sales, including fuel, of 19.6% and 14.6% for the three and nine months ended October 31, 2021, respectively. Growth in comparable sales benefited from growth in transactions and average ticket and was aided by consumer spending due to government stimulus, and also includes some higher inflation impacts in certain merchandise categories compared to recent years. The growth in comparable sales was partially offset by our decision to remove tobacco from certain club locations. Sam's Club eCommerce net sales positively contributed approximately 1.1% and 1.7% to comparable sales for the three and nine months ended October 31, 2021, respectively.

Gross profit rate decreased 127 and 75 basis points for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The gross profit rates were negatively impacted by higher supply chain costs, increased fuel sales which have lower margins, and cost inflation. The decrease in gross profit rate for the nine months ended October 31, 2021 was partially offset by favorable sales mix, including reduced tobacco sales.

Membership and other income increased 14.4% and 13.0% for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The increases were due to increases in overall renewal rates, new member sign-ups and Plus penetration.

Operating expenses as a percentage of segment net sales decreased 117 and 73 basis points for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year. The decreases were primarily the result of higher fuel sales as well as a benefit from lower incremental COVID-19 related costs. The decrease in operating expense as a percentage of segment net sales for the nine months ended October 31, 2021 was partially offset by reduced tobacco sales.

As a result of the factors discussed above, operating income increased \$44 million and \$193 million for the three and nine months ended October 31, 2021, respectively, when compared to the same periods in the previous fiscal year.

Liquidity and Capital Resources

Liquidity

The strength and stability of our operations have historically supplied us with a significant source of liquidity. Our cash flows provided by operating activities, supplemented with our long-term debt and short-term borrowings, have been sufficient to fund our operations while allowing us to invest in activities that support the long-term growth of our operations. Generally, some or all of the remaining available cash flow has been used to fund the dividends on our common stock and share repurchases. In the current environment, we believe our sources of liquidity will continue to be adequate to fund operations, finance our global investment and expansion activities, pay dividends and fund our share repurchases for the foreseeable future.

Net Cash Provided by Operating Activities

	Nine Months Ended October 31,				
(Amounts in millions)	2021	2020			
Net cash provided by operating activities	\$ 16,291	\$ 22,880			

Net cash provided by operating activities was \$16.3 billion and \$22.9 billion for the nine months ended October 31, 2021 and 2020, respectively. The decrease in cash provided by operating activities for the nine months ended October 31, 2021 was primarily due to an increase in inventory purchases to support strong sales and lapping the impact of accelerated inventory sell-through in fiscal 2021, as well as timing and payment of wages.

Cash Equivalents and Working Capital Deficit

Cash and cash equivalents were \$16.1 billion and \$14.3 billion at October 31, 2021 and 2020, respectively. Our working capital deficit was \$4.7 billion as of October 31, 2021, which decreased when compared to \$14.5 billion as of October 31, 2020, primarily driven by the increase in inventory described above. We generally operate with a working capital deficit due to our efficient use of cash in funding operations, consistent access to the capital markets and returns provided to our shareholders in the form of payments of cash dividends and share repurchases.

As of October 31, 2021 and January 31, 2021, cash and cash equivalents of \$5.5 billion and \$2.8 billion, respectively, may not be freely transferable to the U.S. due to local laws or other restrictions. Of the \$5.5 billion at October 31, 2021, approximately \$2.8 billion can only be accessed through dividends or intercompany financing arrangements subject to approval of the Flipkart minority shareholders; however, this cash is expected to be utilized to fund the operations of Flipkart.

Net Cash Used in Investing Activities

	Nine Months E	Ended October 31,
(Amounts in millions)	2021	2020
Net cash used in investing activities	\$ (1,530)	\$ (6,507)

Net cash used in investing activities was \$1.5 billion as compared to \$6.5 billion for the nine months ended October 31, 2021 and 2020, respectively. Net cash used in investing activities decreased \$5.0 billion for the nine months ended October 31, 2021 primarily due to the net proceeds received from the divestitures of Asda and Seiyu, partially offset by increased capital expenditures.

Growth activities

For the fiscal year ending January 31, 2022, we project capital expenditures will be approximately \$13 billion, with a focus on supply chain, automation, customer-facing initiatives and technology. Refer to the "Strategic Capital Allocation" section in our Company Performance Metrics for capital expenditure detail for the nine months ended October 31, 2021 and 2020.

Net Cash Used in Financing Activities

	Nine Months E	nded October 31,
(Amounts in millions)	2021	2020
Net cash used in financing activities	\$ (18,113)	\$ (11,340)

Net cash from financing activities generally consists of transactions related to our short-term and long-term debt, dividends paid and the repurchase of the Company's common stock. Transactions with noncontrolling interest shareholders are also classified as cash flows from financing activities. Net cash used in financing activities was \$18.1 billion as compared to \$11.3 billion for the nine months ended October 31, 2021 and 2020, respectively. The increase in net cash used in financing activities is primarily due to repayments of long-term debt and related payment of premiums for the early extinguishment of certain notes, as well as increased share repurchases, partially offset by new long-term debt issuances in the current year and equity funding from the sale of subsidiary stock. During the nine months ended October 31, 2021, the Company received \$3.2 billion related to the sale of stock by certain of its subsidiaries, primarily related to a new equity funding which reduced the Company's ownership of its majority-owned Flipkart subsidiary from approximately 83% as of January 31, 2021, to approximately 75%.

In April 2021, the Company renewed and extended its existing 364-day revolving credit facility of \$10.0 billion as well as its five-year credit facility of \$5.0 billion. In total, we had committed lines of credit in the U.S. of \$15.0 billion at October 31, 2021, all undrawn.

Long-term Debt

The following table provides the changes in our long-term debt for the nine months ended October 31, 2021:

	Long-term debt due within	n			
(Amounts in millions)	one year		Long-term d	lebt	Total
Balances as of February 1, 2021	\$ 3,11	15	\$	41,194	\$ 44,309
Proceeds from issuance of long-term debt	-	_		6,945	6,945
Repayments of long-term debt	(3,01	10)		(10,000)	(13,010)
Reclassifications of long-term debt	1,46	61		(1,461)	_
Other		9		(253)	(244)
Balances as of October 31, 2021	\$ 1,57	75	\$	36,425	\$ 38,000

Our total outstanding long-term debt decreased \$6.3 billion during the nine months ended October 31, 2021, primarily due to the extinguishment and maturities of certain long-term debt, partially offset by the issuance of new long-term debt in September 2021. Refer to Note 4 to our Condensed Consolidated Financial Statements for details on the maturities, extinguishment and issuances of long-term debt. The early extinguishment of certain long-term debt allowed us to retire higher rate debt to reduce interest expense in future periods. In connection with this early extinguishment of debt, the Company paid premiums of \$2.3 billion, which represents the majority of the \$2.4 billion loss recorded on the transaction during the nine months ended October 31, 2021.

Dividends

Effective February 18, 2021, the Board of Directors approved the fiscal 2022 annual dividend of \$2.20 per share, an increase over the fiscal 2021 annual dividend of \$2.16 per share. For fiscal 2022, the annual dividend was or will be paid in four quarterly installments of \$0.55 per share, according to the following record and payable dates:

Record Date	Payable Date
March 19, 2021	April 5, 2021
May 7, 2021	June 1, 2021
August 13, 2021	September 7, 2021
December 10, 2021	January 3, 2022

The dividend installments payable on April 5, 2021, June 1, 2021 and September 7, 2021 were paid as scheduled.

Company Share Repurchase Program

From time to time, the Company repurchases shares of its common stock under share repurchase programs authorized by the Company's Board of Directors. All repurchases made prior to February 22, 2021 were made under the plan in effect at the beginning of fiscal 2022. On February 18, 2021, the Board of Directors approved a new \$20.0 billion share repurchase program which has no expiration date or other restrictions limiting the period over which the Company can make repurchases, and beginning February 22, 2021, replaced the previous share repurchase program. As of October 31, 2021, authorization for \$13.1 billion of share repurchases remained under the share repurchase program. Any repurchased shares are constructively retired and returned to an unissued status.

We regularly review share repurchase activity and consider several factors in determining when to execute share repurchases, including, among other things, current cash needs, capacity for leverage, cost of borrowings, our results of operations and the market price of our common stock. We anticipate that a majority of the ongoing share repurchase program will be funded through the Company's free cash flow. The following table provides, on a settlement date basis, share repurchase information for the nine months ended October 31, 2021 and 2020:

	Nine Months Er	ded Oc	tober 31,
(Amounts in millions, except per share data)	 2021		2020
Total number of shares repurchased	52.7		9.6
Average price paid per share	\$ 139.76	\$	123.54
Total amount paid for share repurchases	\$ 7,368	\$	1,186

Capital Resources

We believe cash flows from operations, our current cash position and access to capital markets will continue to be sufficient to meet our anticipated operating cash needs, which include funding seasonal increases in merchandise inventories, our capital expenditures, acquisitions, dividend payments and share repurchases.

We have strong commercial paper and long-term debt ratings that have enabled and should continue to enable us to refinance our debt as it becomes due at favorable rates in the capital markets. We also have \$15.0 billion in various committed lines of credit in the U.S., all of which currently remains undrawn. At October 31, 2021, the ratings assigned to our commercial paper and rated series of our outstanding long-term debt were as follows:

Rating agency	Commercial paper	Long-term debt
Standard & Poor's	A-1+	AA
Moody's Investors Service	P-1	Aa2
Fitch Ratings	F1+	AA

Credit rating agencies review their ratings periodically and, therefore, the credit ratings assigned to us by each agency may be subject to revision at any time. Accordingly, we are not able to predict whether our current credit ratings will remain consistent over time. Factors that could affect our credit ratings include changes in our operating performance, the general economic environment, conditions in the retail industry, our financial position, including our total debt and capitalization, and changes in our business strategy. Any downgrade of our credit ratings by a credit rating agency could increase our future borrowing costs or impair our ability to access capital and credit markets on terms commercially acceptable to us. In addition, any downgrade of our current short-term credit ratings could impair our ability to access the commercial paper markets with the same flexibility that we have experienced historically, potentially requiring us to rely more heavily on more expensive types of debt financing. The credit rating agency ratings are not recommendations to buy, sell or hold our commercial paper or debt securities. Each rating may be subject to revision or withdrawal at any time by the assigning rating organization and should be evaluated independently of any other rating. Moreover, each credit rating is specific to the security to which it applies.

Other Matters

In Note 7 to our Condensed Consolidated Financial Statements, which is captioned "Contingencies" and appears in Part I of this Quarterly Report on Form 10-Q under the caption "Item 1. Financial Statements," we discuss, under the sub-caption "Opioids Litigation," the Prescription Opiate Litigation and other matters, including certain risks arising therefrom. In that Note 7, we also discuss, under the sub-caption "Asda Equal Value Claims," the Company's indemnification obligation for the Asda Equal Value Claims matter. We discuss various legal proceedings related to the Federal and State Prescription Opiate Litigation, DOJ Opioid Civil Litigation and Opioids Related Securities Class Actions and Derivative Litigation in Part II of this Quarterly Report on Form 10-Q under the caption "Item 1. Legal Proceedings," under the sub-caption "I. Supplemental Information." We also discuss items related to the Asda Equal Value Claims matter, the Money Transfer Agent Services Proceedings matter and the Foreign Direct Investment matters in Part II of this Quarterly Report on Form 10-Q under the caption "Item 1. Legal Proceedings," under the sub-caption "II. Certain Other Matters." We also discuss an environmental matter with the State of California in Part II of this Quarterly Report on Form 10-Q under the caption "Item 1. Legal Proceedings," under the sub-caption "III. Environmental Matters." The foregoing matters and other matters described elsewhere in this Quarterly Report on Form 10-Q represent contingent liabilities of the Company that may or may not result in the incurrence of a material liability by the Company upon their final resolution.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risks relating to our operations result primarily from changes in interest rates, currency exchange rates and the fair value of certain equity investments. As of October 31, 2021, there were no material changes to our market risks disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The information concerning market risk set forth in Part II, Item 7A. of our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, as filed with the SEC on March 19, 2021, under the caption "Quantitative and Qualitative Disclosures About Market Risk," is hereby incorporated by reference into this Quarterly Report on Form 10-Q.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information, which is required to be timely disclosed, is accumulated and communicated to management in a timely fashion. In designing and evaluating such controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management is necessarily required to use judgment in evaluating controls and procedures. Also, we have investments in unconsolidated entities. Since we do not control or manage those entities, our controls and procedures with respect to those entities are substantially more limited than those we maintain with respect to our consolidated subsidiaries.

In the ordinary course of business, we review our internal control over financial reporting and make changes to our systems and processes to improve such controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, updating existing systems, automating manual processes, standardizing controls globally, migrating certain processes to our shared services organizations and increasing monitoring controls. These changes have not materially affected, and are not reasonably likely to materially affect, the Company's internal control over financial reporting and they allow us to continue to enhance our internal controls over financial reporting and ensure that they remain effective.

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report was performed under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC's rules and forms.

There has been no change in the Company's internal control over financial reporting during the most recently completed fiscal quarter, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

I. SUPPLEMENTAL INFORMATION: We discuss certain legal proceedings in Part I of this Quarterly Report on Form 10-Q under the caption "Item 1. Financial Statements," in Note 7 to our Condensed Consolidated Financial Statements, which is captioned "Contingencies," under the sub-caption "Legal Proceedings." We refer you to that discussion for important information concerning those legal proceedings, including the basis for such actions and, where known, the relief sought. We provide the following additional information concerning those legal proceedings, including the name of the lawsuit, the court in which the lawsuit is pending, and the date on which the petition commencing the lawsuit was filed.

Prescription Opiate Litigation: In re National Prescription Opiate Litigation (MDL No. 2804) (the "MDL"). The MDL is pending in the U.S. District Court for the Northern District of Ohio and includes over 2,100 cases as of November 22, 2021, some of which cases are in the process of being transferred to the MDL or have remand motions pending. The liability phase of a trial in one of the MDL cases began on October 4, 2021 against a number of parties, including the Company, regarding opioid dispensing claims. On November 23, 2021, the jury found in favor of the plaintiffs as to the liability of all defendants, including the Company. The Company intends to appeal this verdict. There is one case in which the Company is named as a defendant that was remanded from the MDL court to the U.S. District Court for the Eastern District of Oklahoma, where trial is currently scheduled to begin in September 2022. In addition, there are over 200 state court cases pending as of November 22, 2021, some of which may be removed to federal court to seek MDL transfer. The case citations for the state court cases are listed on Exhibit 99.1 to this Quarterly Report on Form 10-Q.

DOJ Opioid Civil Litigation: On October 22, 2020, the Company filed a declaratory judgment action in the U.S. District Court for the Eastern District of Texas against the U.S. Department of Justice (the "DOJ") and the U.S. Drug Enforcement Administration, asking a federal court to clarify the roles and responsibilities of pharmacists and pharmacies as to the dispensing and distribution of opioids under the Controlled Substances Act (the "CSA"). The Company's action, *Walmart Inc. v. U.S. Department of Justice et al.*, USDC, Eastern Dist. of Texas, 10/22/20, was dismissed. The Company has appealed this decision to the Fifth Circuit and awaits the court's decision. A civil complaint pending in the U.S. District Court for the District of Delaware has been filed by the DOJ against the Company, in which the DOJ alleges violations of the CSA related to nationwide distribution and dispensing of opioids. *U.S. v. Walmart Inc., et al.*, USDC, Dist. of DE, 12/22/20. The Company filed a motion to dismiss the DOJ complaint on February 22, 2021. The DOJ filed its opposition brief on April 23, 2021 and the Company filed its reply brief on May 24, 2021. On November 19, 2021, the District Court stayed further proceedings in the DOJ complaint pending the decision of the United States Supreme Court in two other cases interpreting the CSA, which have been consolidated into *Ruan v. United States*, __, S. Ct. __,2021 WL 5148067 (U.S. Nov. 5, 2021) (mem.).

Opioids Related Securities Class Actions and Derivative Litigation: Three derivative complaints and two securities class action lawsuits drawing heavily on the allegations of the DOJ complaint have been filed in Delaware naming various current and former directors and certain officers as defendants. The plaintiffs in the derivative suits (in which the Company is a nominal defendant) allege, among other things, that the defendants breached their fiduciary duties in connection with oversight of opioids dispensing and distribution; and that the defendants violated Section 14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are liable for contribution under Section 10(b) of the Exchange Act in connection with the Company's disclosures about opioids. The securities class actions, alleging violations of Sections 10(b) and 20(a) of the Exchange Act regarding the Company's disclosures with respect to opioids, were purportedly filed on behalf of a class of investors who acquired Walmart stock from March 30, 2016 through December 22, 2020. On May 11, 2021, the court consolidated the class actions and appointed a lead plaintiff and lead counsel. The defendants filed a motion to dismiss the consolidated securities class action on October 8, 2021.

Derivative Lawsuits: Abt v. Alvarez et al., USDC, Dist. of DE, 2/9/21; Nguyen v. McMillon et al., USDC, Dist. of DE, 4/16/21: Ontario Provincial Council of Carpenters' Pension Trust Fund et al. v. Walton et al., DE Court of Chancery, 9/27/21.

Securities Class Actions: Stanton v. Walmart Inc. et al., USDC, Dist. of DE, 1/20/21 and Martin v. Walmart Inc. et al., USDC, Dist. of DE, 3/5/21, consolidated into In re Walmart Inc. Securities Litigation, USDC, Dist. of DE, 5/11/21.

II. CERTAIN OTHER MATTERS

ASDA Equal Value Claims: Ms S Brierley & Others v ASDA Stores Ltd (2406372/2008 & Others - Manchester Employment Tribunal); ASDA Stores Ltd v Brierley & Ors (A2/2016/0973 - United Kingdom Court of Appeal); ASDA Stores Ltd v Ms S Brierley & Others (UKEAT/0059/16/DM - United Kingdom Employment Appeal Tribunal); and ASDA Stores Ltd v Ms S Brierley & Others (UKEAT/0009/16/JOJ - United Kingdom Employment Appeal Tribunal).

Money Transfer Agent Services Proceedings: The Company has received grand jury subpoenas issued by the United States Attorney's Office for the Middle District of Pennsylvania seeking documents regarding the Company's consumer fraud program and anti-money laundering compliance related to the Company's money transfer services, where Walmart is an agent. The most recent subpoena was issued in August 2020. The Company has been responding to these subpoenas and is cooperating with the government's investigation. The Company has also responded to civil investigative demands from the United States Federal Trade Commission (the "FTC") and is cooperating with the FTC's investigation related to money transfers and the Company's anti-fraud program in its capacity as an agent. While the Company had been engaged in discussions with the FTC regarding a potential resolution of this matter, the parties have not been able to reach a resolution. The FTC staff recently forwarded a draft civil complaint to the FTC seeking authority to file a complaint against the Company seeking various forms of monetary and injunctive relief. The FTC is currently considering whether to grant such authorization. The Company is unable to predict the final outcome of the investigations, any discussions, or any related actions by the governmental entities regarding these matters. While the Company does not currently believe that the final outcome of these matters will have a material adverse effect on its business, financial condition, results of operations or cash flows, the Company can provide no assurance as to the scope and final outcome of these matters and whether its business, financial position, results of operations or cash flows will not be materially adversely affected.

Foreign Direct Investment Matters: In July 2021, the Directorate of Enforcement in India issued a show cause notice to Flipkart Private Limited and one of its subsidiaries ("Flipkart"), and to unrelated companies and individuals, including certain current and former shareholders and directors of Flipkart. The notice requests the recipients to show cause as to why further proceedings under India's Foreign Direct Investment rules and regulations (the "Rules") should not be initiated against them based on alleged violations during the period from 2009 to 2015, prior to the Company's acquisition of a majority stake in Flipkart in 2018. The notice is an initial stage of proceedings under the Rules which could, depending upon the conclusions at the end of the initial stage, lead to a hearing to consider the merits of the allegations described in the notice. If a hearing is initiated and if it is determined that violations of the Rules occurred, the regulatory authority has the authority to impose monetary and/or non-monetary relief. Flipkart has begun the process of responding to the notice and, if the matter progresses to a consideration of the merits of the allegations described in the notice is initiated, Flipkart intends to defend against the allegations vigorously. Due to the fact that this process is in an early stage, the Company is unable to predict whether the notice will lead to a hearing on the merits or, if it does, the final outcome of the resulting proceedings. While the Company does not currently believe that this matter will have a material adverse effect on its business, financial condition, results of operations or cash flows, the Company can provide no assurance as to the scope or outcome of any proceeding that might result from the notice, the amount of the proceeds the Company may receive in indemnification from individuals and entities that sold shares to the Company under the 2018 agreement pursuant to which the Company acquired its majority stake in Flipkart, or whether the Company's business,

III. ENVIRONMENTAL MATTERS: Item 103 of SEC Regulation S-K requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions that the Company reasonably believes will exceed an applied threshold of \$1 million.

In June 2021, the Company signed a tolling agreement with the Office of the Attorney General of the State of California to toll the statute of limitations for potential claims regarding Walmart's management of waste consumer products at its California facilities that are alleged to be hazardous. The Company is presently engaged in settlement discussions. It is not presently known whether a settlement will be reached or enforcement action will ensue, but the potential for penalties or settlement costs could exceed \$1 million. The Company does not believe that this matter will have a material adverse effect on its business, financial position, results of operations, or cash flows.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Part I, Item 1A, under the caption "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended January 31, 2021 which risks could materially and adversely affect our business, results of operations, financial condition, and liquidity. No material change in the risk factors discussed in such Form 10-K has occurred. Such risk factors do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. Our business operations could also be affected by additional factors that apply to all companies operating in the U.S. and globally.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

From time to time, the Company repurchases shares of its common stock under share repurchase programs authorized by the Company's Board of Directors. All repurchases made prior to February 22, 2021 were made under the plan in effect at the beginning of fiscal 2022. On February 18, 2021, the Board of Directors approved a new \$20.0 billion share repurchase program which has no expiration date or other restrictions limiting the period over which the Company can make repurchases, and beginning February 22, 2021, replaced the previous share repurchase program. As of October 31, 2021, authorization for \$13.1 billion of share repurchases remained under the share repurchase program. Any repurchased shares are constructively retired and returned to an unissued status.

The Company regularly reviews its share repurchase activity and considers several factors in determining when to execute share repurchases, including, among other things, current cash needs, capacity for leverage, cost of borrowings and the market price of its common stock. Share repurchase activity under our share repurchase program, on a trade date basis, for the three months ended October 31, 2021, was as follows:

Fiscal Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs ⁽¹⁾ (billions)
August 1 - 31, 2021	4,470,493	\$ 147.73	4,470,493	\$ 14.6
September 1 - 30, 2021	4,988,810	144.55	4,988,810	13.9
October 1 - 31, 2021	5,315,215	141.62	5,315,215	13.1
Total	14,774,518		14,774,518	

⁽¹⁾ Represents approximate dollar value of shares that could have been purchased under the plan in effect at the end of the month.

Item 5. Other Information

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements that Walmart believes are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that Act as well as protections afforded by other federal securities laws.

Forward-looking Statements

The forward-looking statements in this report include, among other things:

- statements in Note 4 to those Condensed Consolidated Financial Statements regarding the intended uses of proceeds from certain bond offerings;
- statements in Note 7 to those Condensed Consolidated Financial Statements regarding the possible outcome of, and future effect on Walmart's financial condition and results of operations of, certain litigation and other proceedings to which Walmart is a party, the possible outcome of, and future effect on Walmart's business of, certain other matters to which Walmart is subject, including the Company's Opioids Litigation as well as Walmart's ongoing indemnification obligation for the Asda Equal Value Claims and the liabilities, losses, expenses and costs that Walmart may incur in connection with such matters;
- in Part I, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations": statements regarding future changes to our business and our expectations about the potential impacts on our business, financial position, results of operations or cash flows as a result of the COVID-19 pandemic; statements under the caption "Overview" relating to the possible impact of volatility in currency exchange rates on the results, including net sales and operating income, of Walmart and the Walmart International segment; statements under the caption "Company Performance Metrics Strong, Efficient Growth" regarding the focus of our investments and the impact of such investments; statements under the caption "Company Performance Metrics Strategic Capital Allocation"

regarding our strategy and discipline for capital allocation; statements under the caption "Company Performance Metrics - Returns" regarding our belief that returns on capital will improve as we execute on our financial framework; statements under the caption "Results of Operations - Consolidated Results of Operations" regarding the possibility of fluctuations in Walmart's effective income tax rate from quarter to quarter and the factors that may cause those fluctuations; a statement under the caption "Results of Operations - Sam's Club Segment" relating to the possible continuing impact of volatility in fuel prices on the future operating results of the Sam's Club segment; a statement under the caption "Liquidity and Capital Resources - Liquidity." that Walmart's sources of liquidity will be adequate to fund its operations, finance its global investment and expansion activities, pay dividends and fund share repurchases; statements under the caption "Liquidity and Capital Resources - Liquidity - Net Cash Provided by Operating Activities - Cash Equivalents and Working Capital Deficit" regarding management's expectation that cash in market will be utilized to fund Flipkart's operations; a statement under the caption "Liquidity and Capital Resources Liquidity - Net Cash Used in Financing Activities - Dividends" regarding the payment of dividends in fiscal 2022; a statement under the caption "Liquidity and Capital Resources Liquidity - Net Cash Used in Financing Activities - Company Share Repurchase Program" regarding funding of our share repurchase program; statements under the caption "Liquidity and Capital Resources" regarding management's expectations regarding the Company's cash flows from operations, current cash position and access to capital markets continuing to be sufficient to meet its anticipated operating cash needs, the Company's commercial paper and long-term debt ratings continuing to enable it to refinance its debts at favorable rates, factors that could affect its credit ratings, and the effect th

- in Part I, Item 4 "Controls and Procedures": statements regarding the effect of changes to systems and processes on our internal control over financial reporting; and
- in Part II, Item 1 "Legal Proceedings": statements regarding the effect that possible losses or the range of possible losses that might be incurred in connection with the legal proceedings and other matters discussed therein may have on our financial condition or results of operations.

Risks, Factors and Uncertainties Regarding Our Business

These forward-looking statements are subject to risks, uncertainties and other factors, domestically and internationally, including:

Economic Factors

- economic, geo-political, capital markets and business conditions, trends and events around the world and in the markets in which Walmart operates;
- currency exchange rate fluctuations;
- · changes in market rates of interest;
- · changes in market levels of wages;
- · changes in the size of various markets, including eCommerce markets;
- unemployment levels;
- inflation or deflation, generally and in certain product categories;
- transportation, energy and utility costs;
- commodity prices, including the prices of oil and natural gas;
- · consumer confidence, disposable income, credit availability, spending levels, shopping patterns, debt levels, and demand for certain merchandise;
- trends in consumer shopping habits around the world and in the markets in which Walmart operates;
- · consumer enrollment in health and drug insurance programs and such programs' reimbursement rates and drug formularies; and
- initiatives of competitors, competitors' entry into and expansion in Walmart's markets or lines of business, and competitive pressures.

Operating Factors

- the amount of Walmart's net sales and operating expenses denominated in U.S. dollar and various foreign currencies;
- the financial performance of Walmart and each of its segments, including the amount of Walmart's cash flow during various periods;
- customer transaction and average ticket in Walmart's stores and clubs and on its eCommerce platforms;
- the mix of merchandise Walmart sells and its customers purchase;
- · the availability of goods from suppliers and the cost of goods acquired from suppliers;
- the effectiveness of the implementation and operation of Walmart's strategies, plans, programs and initiatives;
- COVID-19 related challenges, including reduced customer transactions and tickets, reduced store hours, shifts in demand from discretionary products, supply chain disruption and production, labor shortages and increases in labor costs, and dissemination of global vaccines, as well as potential impacts of any related vaccine mandates on our workforce;
- the impact of acquisitions, divestitures, store or club closures, and other strategic decisions;
- Walmart's ability to successfully integrate acquired businesses;
- unexpected changes in Walmart's objectives and plans;
- the amount of shrinkage Walmart experiences;
- · consumer acceptance of and response to Walmart's stores and clubs, eCommerce platforms, programs, merchandise offerings and delivery methods;
- · Walmart's gross profit margins, including pharmacy margins and margins of other product categories;
- the selling prices of gasoline and diesel fuel;
- disruption of seasonal buying patterns in Walmart's markets;
- · disruptions in Walmart's supply chain and inventory management;
- · cybersecurity events affecting Walmart and related costs and impact of any disruption in business;
- · Walmart's labor costs, including healthcare and other benefit costs;
- · Walmart's casualty and accident-related costs and insurance costs;
- the size of and turnover in Walmart's workforce and the number of associates at various pay levels within that workforce;
- the availability of necessary personnel to staff Walmart's stores, clubs and other facilities;
- · delays in the opening of new, expanded, relocated or remodeled units;
- developments in, and the outcome of, legal and regulatory proceedings and investigations to which Walmart is a party or is subject, and the liabilities, obligations and expenses, if any, that Walmart may incur in connection therewith;
- changes in the credit ratings assigned to the Company's commercial paper and debt securities by credit rating agencies;
- Walmart's effective tax rate; and
- · unanticipated changes in accounting judgments and estimates.

Regulatory and Other Factors

- changes in existing, tax, labor and other laws and changes in tax rates, including the enactment of laws and the adoption and interpretation of administrative rules and regulations:
- · the imposition of new taxes on imports, new tariffs and changes in existing tariff rates;
- the imposition of new trade restrictions and changes in existing trade restrictions;
- adoption or creation of new, and modification of existing, governmental policies, programs, initiatives and actions in the markets in which Walmart operates and elsewhere and actions with respect to such policies, programs and initiatives;
- changes in government-funded benefit programs and the extent and effectiveness of any further COVID-19 related stimulus packages;
- changes in currency control laws;
- changes in the level of public assistance payments;
- · one or more prolonged federal government shutdowns;
- the timing of federal income tax refunds;
- · natural disasters, changes in climate, catastrophic events and global health epidemics or pandemics, including COVID-19; and
- changes in generally accepted accounting principles in the United States.

Other Risk Factors; No Duty to Update

This Quarterly Report on Form 10-Q should be read in conjunction with Walmart's Annual Report on Form 10-K for the fiscal year ended January 31, 2021 and all of Walmart's subsequent other filings with the Securities and Exchange Commission. Walmart urges investors to consider all of the risks, uncertainties and other factors disclosed in these filings carefully in evaluating the forward-looking statements contained in this Quarterly Report on Form 10-Q. The Company cannot assure you that the results or developments anticipated by the Company and reflected or implied by any forward-looking statement contained in this Quarterly Report on Form 10-Q will be realized or, even if substantially realized, that those results or developments will result in the forecasted or expected consequences for the Company or affect the Company, its operations or its financial performance as the Company has forecasted or expected. As a result of the matters discussed above and other matters, including changes in facts, assumptions not being realized or other factors, the actual results relating to the subject matter of any forward-looking statement in this Quarterly Report on Form 10-Q may differ materially from the anticipated results expressed or implied in that forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this report, and Walmart undertakes no obligation to update any such statements to reflect subsequent events or circumstances.

Item 6. Exhibits

The following documents	are filed as an exhibit to this	Ouarterly Re	port on Form 10-O:

Exhibit 3.1	Restated Certificate of Incorporation of the Company dated Februar	v 1 2018 is incorporated herein b	w reference to Exhibit 3.1 to the Current Report on
LAMOR J. I	Restated Certificate of incorporation of the Company dated reordar	v 1, 2010 is incorporated nerein t	by reference to Exhibit 3.1 to the Current Report on

Form 8-K that the Company filed on February 1, 2018

Exhibit 3.2 Amended and Restated Bylaws of the Company dated July 23, 2019 are incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-

K that the Company filed on July 26, 2019

Exhibit 4.1 Series Terms Certificate Pursuant to the Indenture Relating to 1.050% Notes Due 2026 of the Company is incorporated herein by reference to Exhibit 4.1

to the Current Report on Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.2 Series Terms Certificate Pursuant to the Indenture Relating to 1,500% Notes Due 2028 of the Company is incorporated herein by reference to Exhibit 4.2

to the Current Report on Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.3 Series Terms Certificate Pursuant to the Indenture Relating to 1.800% Notes Due 2031 of the Company is incorporated herein by reference to Exhibit 4.3

to the Current Report on Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.4 Series Terms Certificate Pursuant to the Indenture Relating to 2,500% Notes Due 2041 of the Company is incorporated herein by reference to Exhibit 4.4

to the Current Report on Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.5 Series Terms Certificate Pursuant to the Indenture Relating to 2.650% Notes Due 2051 of the Company is incorporated herein by reference to Exhibit 4.5

to the Current Report on Form 8-K that the Company filed on September 15, 2021.

Exhibit 4 6 Form of Global Note to represent the 1.050% Notes Due 2026 of the Company is incorporated herein by reference to Exhibit 4.6 to the Current Report on

Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.7 Form of Global Note to represent the 1.500% Notes Due 2028 of the Company is incorporated herein by reference to Exhibit 4.7 to the Current Report on

Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.8 Form of Global Note to represent the 1.800% Notes Due 2031 of the Company is incorporated herein by reference to Exhibit 4.8 to the Current Report on

Form 8-K that the Company filed on September 15, 2021.

Form of Global Note to represent the 2.500% Notes Due 2041 of the Company is incorporated herein by reference to Exhibit 4.9 to the Current Report on Exhibit 4.9

Form 8-K that the Company filed on September 15, 2021.

Exhibit 4.10 Form of Global Note to represent the 2.650% Notes Due 2051 of the Company is incorporated herein by reference to Exhibit 4.10 to the Current Report

on Form 8-K that the Company filed on September 15, 2021.

Exhibit 31.1* Chief Executive Officer Section 302 Certification Exhibit 31.2* Chief Financial Officer Section 302 Certification Exhibit 32.1** Chief Executive Officer Section 906 Certification Exhibit 32.2** Chief Financial Officer Section 906 Certification

Exhibit 99.1* State Court Opioids Litigation Case Citations and Currently Scheduled Trial Dates

Exhibit 101.INS* Inline XBRL Instance Document

Exhibit 101.SCH* Inline XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document Exhibit 101 DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document Exhibit 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document Exhibit 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document

The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended October 31, 2021, formatted in Inline XBRL (included in Exhibit 101) Exhibit 104

- Filed herewith as an Exhibit.
- Furnished herewith as an Exhibit.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		WALMART INC.
Date: December 1, 2021	By:	/s/ C. Douglas McMillon
		C. Douglas McMillon President and Chief Executive Officer (Principal Executive Officer)
Date: December 1, 2021	Ву:	/s/ M. Brett Biggs
		M. Brett Biggs Executive Vice President and Chief Financial Officer (Principal Financial Officer)
Date: December 1, 2021	By:	/s/ David M. Chojnowski
Bute. December 1, 2021	By.	David M. Chojnowski Senior Vice President and Controller (Principal Accounting Officer)

I, C. Douglas McMillon, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Walmart Inc. (the "registrant");
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
 material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
 during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluations; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of registrant's Board of Directors:
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 1, 2021 /s/ C. Douglas McMillon

C. Douglas McMillon President and Chief Executive Officer

I, M. Brett Biggs, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Walmart Inc. (the "registrant");
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
 material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
 during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluations; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of registrant's Board of Directors:
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 1, 2021

/s/ M. Brett Biggs

M. Brett Biggs

Executive Vice President and Chief Financial Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of Walmart Inc. (the "Company") on Form 10-Q for the period ending October 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, C. Douglas McMillon, President and Chief Executive Officer of the Company, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

IN WITNESS WHEREOF, the undersigned has executed this Certificate, effective as of December 1, 2021.

/s/ C. Douglas McMillon

C. Douglas McMillon President and Chief Executive Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of Walmart Inc. (the "Company") on Form 10-Q for the period ending October 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, M. Brett Biggs, Executive Vice President and Chief Financial Officer of the Company, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

IN WITNESS WHEREOF, the undersigned has executed this Certificate, effective as of December 1, 2021.

/s/ M. Brett Biggs

M. Brett Biggs Executive Vice President and Chief Financial Officer

A. Case Citations For Pending State Court Cases as of November 22, 2021

Mercer Cty. v. Anda Inc., et al., Pa. Ct. Com. Pl., Mercer Cty., 10/22/2021; Clinton Cty. v. Anda, Inc., et al., Pa. Ct. Com. Pl., Clinton Cty., 10/22/2021; City of Lock Haven v. Par Pharm., Inc., et al., Pa. Ct. Com. Pl., Clinton Cty., 10/22/2021; Warminster Twp. v. Par Pharm. Inc., et al., Pa. Ct. Com. Pl., Bucks Cty., 10/12/2021; Warrington Twp. v. Par Pharm. Inc., et al., Pa. Ct. Com. Pl., Bucks Cty., 10/12/2021; Bucks Cty. v. Anda Inc., et al., Pa. Ct. Com. Pl., Bucks Cty., 9/22/2021; Fort Payne Hosp. Corp., et al. v. McKesson Corp., et al., Ala. Cir. Ct., Conecuh Cty., 3/26/2021; State of West Virginia ex rel. Morrisey v. Walmart, Inc., W. Va. Cir. Ct., Putnam Cty., 8/18/2020; City of Fernley v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Lyon Cty., 7/30/2020; City of W. Wendover v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Elko Cty., 7/30/2020; Humboldt Cty, v. Teva Pharm, USA, Inc., et al., Nev. Dist. Ct., Humboldt Cty., 7/29/2020; Churchill Cty, v. Teva Pharm, USA, Inc., et al., Nev. Dist. Ct., Churchill Cty., 7/29/2020; Carson City v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Carson City, 7/29/2020; Douglas Cty. v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Douglas Cty., 7/29/2020; City of Sparks v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Washoe Cty., 7/28/2020; Esmeralda Cty. v. Teva Pharm. USA Inc., et al., Nev. Dist. Ct., Esmeralda Cty., 1/28/2020; Esm 7/29/2020; Cty, of Chester v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 6th Jud. Cir., 7/28/2020; Cty, of Marlboro v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 4th Jud. Cir., 7/28/2020; Washoe Cty. v. Teva Pharm. USA, Inc., et al., Nev. Dist. Ct., Washoe Cty., 7/24/2020; Cty. Comm'rs of Grant Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 6/17/2020; Cty. Comm'n of Mineral Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 6/17/2020; Cty. Comm'n of Monroe Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 6/17/2020; Miss. Baptist Med. Ctr. Inc., et al. v. Amneal Pharm., LLC, et al., Miss. 1st Jud. Dist., Hinds Cty. Cir. Ct., 5/15/2020; City of Holly Springs v. Johnson & Johnson, et al., Miss. 3d Jud. Dist., Marshall Cty. Cir. Ct., 5/13/2020; City of Fairmont v. Allergan PLC, et al., W. Va. Cir. Ct., Kanawha Cty., 4/30/2020; Lester E. Cox Med. Ctrs., et al. v. Amneal Pharm. LLC, et al., Mo. Cir. Ct., Greene Cty., 4/14/2020; City of Beckley v. Allergan PLC, et al., W. Va Cir. Ct., Kanawha Cty., 3/3/2020; City of Kingston v. Teva Pharm. USA, Inc., et al., N.Y. Sup. Ct., Suffolk Cty., 2/27/2020; Mayor Elmer Ray Spence ex rel. Town of Delbarton v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Cty. Comm'n of Tucker Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Cty. Comm'n of Hardy Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Sheila Kessler ex rel. Town of Matewan v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Virginia Ann Martin ex rel. City of Mullens v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Thomas Evans, Jr. ex rel. Town of Oceana v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Cty. Comm'n of Preston Cty. v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Maureen Lasky-Setchell ex rel. City of Belington v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Brian Billings ex rel. City of Point Pleasant v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Gary A. Miller ex rel. Town of Junior v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor David Wood ex rel. City of Moundsville v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Mayor Harold E. Miller ex rel. City of Weirton v. Cardinal Health Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 2/20/2020; Cty. of Newberry v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 12/13/2019; City of Clarksburg v. Allergan PLC, et al., W. Va. Cir. Ct., Kanawha Cty., 11/20/2019; City of Richwood v. Allergan PLC, et al., W. Va. Cir. Ct., Kanawha Cty., 11/20/2019; City of White Sulphur Springs v. Allergan PLC, et al., W. Va. Cir. Ct., Kanawha Cty., 11/20/2019; Mobile Cty. Bd. of Health & Family Oriented Primary Health Care Clinic v. Sackler, et al., Ala. Cir. Ct., Mobile Cty., 10/15/2019; Fla. Health Scis. Ctr., Inc., et al. v. Sackler, et al., Fla. Cir. Ct., 17th Jud. Cir., Broward Cty., 9/16/2019; State of Mississippi v. Cardinal Health, Inc., et al., Miss. 1st Jud. Dist., Hinds Cty. Cir. Ct., 9/12/2019; DCH Health Care Auth. v. Purdue Pharma L.P., et al., Ala. Cir. Ct., Conecuh Cty., 9/3/2019; City of Myrtle Beach v. Purdue Pharma L.P., et al., S.C. Ct. Com. Pl., 15th Jud. Cir., 8/29/2019; State of South Dakota ex rel. Ravnsborg v. Purdue Pharma L.P., et al., S.D. Cir. Ct., 6th Jud. Cir., Hughes Cty., 8/27/2019; Town of Canton v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Chicopee v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Framingham v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Gloucester v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Haverhill v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; Town of Lynnfield v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; Town of Natick v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Salem v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Springfield v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; Town of Wakefield v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; City of Worcester v. Purdue Pharma L.P., et al., Mass. Super. Ct., Suffolk Cty., 8/23/2019; Town of Summerville v. Purdue Pharma L.P., et al., S.C. Ct. Com. Pl., 1st Jud. Cir., 8/23/2019; City of N. Las Vegas v. Purdue Pharma, L.P., et al., Nev. Dist. Ct., Clark Cty., 8/22/2019; City of Las Vegas v. Purdue Pharma, L.P., et al., Nev. Dist. Ct., Clark Cty., 8/22/2019; City of Henderson v. Purdue Pharma, L.P., et al., Nev. Dist. Ct., Clark Cty., 8/22/2019; Town of Mt. Pleasant v. Purdue Pharma L.P., et al., S.C. Ct. Com. Pl., 9th Jud. Cir., 8/16/2019; City of Charleston v. Purdue Pharma L.P., et al., S.C. Ct. Com. Pl., 9th Jud. Cir., 8/15/2019; Wasatch Cty. v. Sackler, et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Cache Cty., et al. v. Sackler, et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Sevier Cty., et al. v. Purdue Pharma L.P., et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Washington Cty., et al., V. Sackler, et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Uintah Cty., et al. v. Sackler, et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Summit Cty., 7/26/2019; Summit Cty., 7/26/2019; Ct., 3d Dist., Summit Cty., 7/26/2019; Summit Cty., 7/26/2019; Ct., 3d Dist., Summit Cty., 7/26/2019; Summit Cty., 7/26/2019; Ct., 3d Dist., Summit Cty., 7/26/2019; Summit Cty., 7/26/2019; Ct., 3d Dist., Weber Cty, v. Sackler, et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; Salt Lake Cty, v. Purdue Pharma L.P., et al., Utah Dist. Ct., 3d Dist., Summit Cty., 7/26/2019; City of N. Charleston v. Purdue Pharma L.P., et al., S.C. Ct. Com. Pl., 9th Jud. Cir., 7/26/2019; Mayor Peggy Knotts Barney ex rel. City of Grafton v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 7/2/2019; Mayor Philip Bowers ex rel. City of Philippi v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 7/2/2019; Braxton Cty. Mem'l Hosp., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; Williamson Mem'l Hosp., LLC v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; Wetzel Cty. Hosp. Ass'n v. Purdue Pharma L.P., et al.,

W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; Princeton Cmty, Hosp. Ass'n, Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; Grant Mem'l Hosp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; Cmty. Health Ass'n d/b/a Jackson Gen. Hosp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 6/7/2019; State of Nevada ex. rel. Ford v. McKesson Corp., et al., Nev. Dist. Ct., Clark Cty., 6/1/2019; City of Yonkers v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 5/29/2019; Cty. of Saluda v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 11th Jud. Cir., 5/20/2019; Cty. of Clarendon v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 3d Jud. Cir., 5/20/2019; Cty. of Abbeville v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/20/2019; Roane Cty. Comm'n v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Spencer v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Ripley v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Wood Cty. Comm'n v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of Williamstown v. Mylan Pharm. Inc.,

Cty., 5/8/2019; Wirt Cty. Comm'n v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Town of Elizabeth v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Pleasants Cty. Comm'n v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; City of St. Marys v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Ritchie Cty. Comm'n v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Town of Harrisville v. Mylan Pharm. Inc., et al., W. Va. Cir. Ct., Kanawha Cty., 5/8/2019; Cty. of Beaufort v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 14th Jud. Cir., 5/8/2019; Cty. of Bamberg v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Barnwell v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/7/2019; Cty. of Colleton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., S.C. Ct. Com. al., S.C. Ct. Com. Pl., 14th Jud. Cir., 5/7/2019; Cty. of Fairfield v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 6th Jud. Cir., 5/7/2019; Cty. of Allendale v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 14th Jud. Cir., 5/7/2019; Cty. of Hampton v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 14th Jud. Cir., 5/7/2019; Cty. of Kershaw v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 5th Jud. Cir., 5/7/2019; Cty. of Jasper v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 14th Jud. Cir., 5/7/2019; Cty. of Lee v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 3d Jud. Cir., 5/7/2019; Cty. of Orangeburg v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 1st Jud. Cir., 5/7/2019; Cty. of Williamsburg v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 3d Jud. Cir., 5/7/2019; Cty. of Chesterfield v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 4th Jud. Cir., 5/7/2019; Cty. of Horry v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 15th Jud. Cir., 5/6/2019; City of Albany v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 5/3/2019; City of Plattsburgh v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 5/3/2019; City of Troy v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 5/3/2019; City of Schenectady v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 5/3/2019; Cty. of Lexington v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 11th Jud. Cir., 5/2/2019; Cty. of Marion v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 12th Jud. Cir., 5/2/2019; Cty. of Calhoun v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 1st Jud. Cir., 5/2/2019; Cty. of Dillon v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 4th Jud. Cir., 5/2/2019; Cty. of Lancaster v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 6th Jud. Cir., 5/2/2019; Cty. of Aiken v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 2d Jud. Cir., 5/2/2019; Cty. of Anderson v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 10th Jud. Cir., 5/1/2019; Cty. of Cherokee v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 7th Jud. Cir., 5/1/2019; Cty. of Edgefield v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 11th Jud. Cir., 5/1/2019; Cty. of Florence v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 12th Jud. Cir., 5/1/2019; Cty. of Greenville v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 13th Jud. Cir., 5/1/2019; Cty. of Greenwood v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of Laurens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 8th Jud. Cir., S.C. Ct. Com. Pl., al., S.C. Ct. Com. Pl., 8th Jud. Cir., 5/1/2019; Cty. of McCormick v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 11th Jud. Cir., 5/1/2019; Cty. of Oconee v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 10th Jud. Cir., 5/1/2019; Cty. of Pickens v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 13th Jud. Cir., 5/1/2019; Cty. of Spartanburg v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 3d Jud. Cir., 5/1/2019; Cty. of Union v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 3d Jud. Cir., 5/1/2019; Cty. of Union v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 16th Jud, Cir., 5/1/2019; Cty. of York v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 16th Jud. Cir., 5/1/2019; W. Va. Univ. Hosps. Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Appalachian Reg'l Healthcare, Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Bluefield Hosp. Co., LLC v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Charleston Area Med. Ctr., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Davis Mem'l Hosp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Broaddus Hosp. Ass'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Webster Cty. Mem'l Hosp., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Grafton City Hosp., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Greenbrier VMC, LLC v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Monongalia Cty. Gen. Hosp. Co. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Preston Mem'l Hosp. Corp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Stonewall Jackson Mem'l Hosp. Co. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Oak Hill Hosp. Corp. d/b/a Plateau Med. Ctr. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Camden-Clark Mem'l Hosp. Corp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Charles Town Gen. Hosp. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; City Hosp., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Potomac Valley Hosp. of W. Va., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; Reynolds Mem'l Hosp. Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; St. Joseph's Hosp. of Buckhannon, Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; United Hosp. Ctr., Inc. v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 4/29/2019; City of Cambridge v. Purdue Pharma L.P., et al., Mass. Super. Ct., Middlesex Cty., 4/12/2019; Cty. of Ulster v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 4/10/2019; Cty. of Washington v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 4/1/2019; Town of Randolph v. Purdue Pharma L.P., et al., Mass. Sup. Ct., Suffolk Cty., 3/27/2019; Cty. of Montgomery v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 3/26/2019; Cty. of Herkimer v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 3/26/2019; State of New Mexico ex rel. Balderas v. Purdue Pharma L.P., et al., N.M. Dist. Ct, 1st Jud. Dist., Santa Fe Cty., 3/6/2019; Cty. of Lewis v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 2/26/2019; Cty. of St. Lawrence v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk

Cty., 1/30/2019; Jefferson Cty. v. Williams, et al., Mo. Cir. Ct., 23d Jud. Dist., Jefferson Cty., 1/29/2019; Franklin Cty. v. Williams, et al., Mo. Cir. Ct., 20th Jud. Dist., Franklin Cty., 1/29/2019; City of New York v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 1/16/2019; Cty. Comm'n of Mason Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Barbour Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Mayor Chris Tatum ex rel. Village of Barboursville v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Comm'n of Taylor Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Cty. Comm'n of Taylor Cty. V. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. Cty. Comm'n of Taylor Cty. V. Co 1/11/2019; Cty. Comm'n of Webster Cty. v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Mayor Don E. McCourt ex rel. Town of Addison aka Town of Webster Springs v. Purdue Pharma, L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 1/11/2019; Cty. of Fulton v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 1/8/2019; Cty. of Cortland v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 1/8/2019; Cty. of Ontario v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 1/8/2019; Cty. of Columbia v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 12/1/2018; Cty. of Monroe v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 12/1/2018; Cty. of Wyoming v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/28/2018; Cty. of Greene v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/28/2018; Cty. of Oswego v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/27/2018; Cty. of Schenectady v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/15/2018; Delaware Cty. v. Purdue Pharma L.P., et al., Pa. Ct. Com. Pl., Delaware Cty., 11/14/2018; Cty. of Carbon v. Purdue Pharma L.P., et al., Pa. Ct. Com. Pl., Delaware Cty., 11/14/2018; Carpenters Health & Welfare Fund of Phila. & Vicinity v. Purdue Pharma L.P., et al., Pa. Ct. Com. Pl., Delaware Cty., 11/14/2018; Cty. of Broome v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Cty. of Erie v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Cty. of Orange v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Cty. of Dutchess v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Cty. of Seneca v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Cty. of Sullivan v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 11/13/2018; Johnson Cty. v. Abbott Labs, et al., Tex. Dist. Ct., 152nd Jud. Dist., Harris Cty., 11/2/2018; City of Ithaca v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Rensselaer v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Saratoga v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Schoharie v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Westchester v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Genesee v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Niagara v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Hamilton v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Franklin v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Schuyler v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Clinton v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Clinton v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Cty. of Tompkins v. Purdue Pharma L.P., et al., N.Y. Sup. Ct., Suffolk Cty., 10/23/2018; Monongalia Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 9/28/2018; Upshur Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 9/28/2018; Marion Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 9/28/2018; Doddridge Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 9/28/2018; Randolph Cty, Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 9/28/2018; Cty. of Dorchester v. Rite Aid of S.C., Inc., et al., S.C. Ct. Com. Pl., 1st Jud. Cir., 6/19/2018; Brooke Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Hancock Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Harrison Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Lewis Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Marshall Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Ohio Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Tyler Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017; Wetzel Cty. Comm'n v. Purdue Pharma L.P., et al., W. Va. Cir. Ct., Kanawha Cty., 12/13/2017.

B. Currently Scheduled Trial Dates In Pending State Court Cases as of November 22, 2021

- On June 22, 2021, Walmart, Inc., on behalf of all subsidiaries, affiliates and other related individuals and entities, reached a settlement agreement to pay an immaterial amount to dismiss all claims with prejudice brought by Nassau County, New York ("Nassau") and Suffolk County, New York ("Suffolk") in the opioid actions captioned County of Suffolk v. Purdue Pharma L.P., et al., Index No. 400001/2017 and County of Nassau v. Purdue Pharma L.P., et al., Index No. 400008/2017. The trial for these matters was scheduled to begin on June 8, 2021. As part of the settlement agreement, the Company paid an immaterial amount to Suffolk and Nassau, but continues to deny any liability with respect to the claims raised in these actions.
- 9/6/2022 State of New Mexico ex rel. Balderas v. Purdue Pharma L.P., et al., N.M. Dist. Ct, 1st Jud. Dist., Santa Fe Cty.
- 9/12/2022 State of West Virginia ex rel. Morrisey v. Walmart Inc., et al., W. Va. Cir. Ct., Kanawha Cty.
- 3/20/2023 The DCH Health Care Authority, et al., v. Purdue Pharma LP, et al., Ala. Cir. Ct., Conecuh Cty. (Trial limited to defendants' liability for public nuisance)
- 4/4/2023 Jefferson Cty. v. Williams, et al., Mo. Cir. Ct., 23d Jud. Dist., Jefferson Cty.
- 4/17/2023 State of Nevada ex. rel. Ford v. McKesson Corp., et al., Nev. Dist. Ct., Clark Cty.